System for treating a wound

JP2023551218A5Inactive Publication Date: 2024-12-03AROA BIOSURGERY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023531051
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-24
Filing Date
2021-11-24
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing negative pressure wound therapy systems face challenges such as blockages from clotted blood, fibrin, and tissue debris, uneven fluid distribution due to height differences in the wound, and inefficiencies in fluid collection and treatment delivery, leading to potential infection and reduced healing efficacy.

Method used

A system with a dual lumen conduit and a pump assembly that includes an air inlet valve and a controller to maintain negative pressure by alternating between introducing air and removing fluid, ensuring continuous fluid flow and distribution, while also allowing for the delivery of treatment fluids.

Benefits of technology

The system effectively maintains negative pressure, reduces the risk of occlusion, ensures uniform fluid distribution, and facilitates the delivery of treatment fluids, enhancing wound healing by preventing stagnation and promoting consistent fluid removal.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

1. A system for treating a wound, the system comprising: a wound treatment device, a fluid input upstream of the device, a fluid output downstream of the device, an air inlet valve upstream of the fluid output, an actuator for driving the air inlet valve between open and closed positions, a pump downstream of the fluid input, a motor for driving the pump to provide negative pressure to the device, and a controller configured to: i) open the air inlet valve and operate the pump to maintain a first vacuum pressure in the wound treatment device and introduce air into the wound treatment device, and ii) close the air inlet valve and operate the pump to maintain a second vacuum pressure in the wound treatment device and remove air and fluid from the device.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a system for treating wounds, more specifically to a system for removing fluid from a wound, a system for supplying fluid to a wound and removing fluid from a wound, and related components for such a system. [Background technology]

[0002] The technique of applying negative pressure to manage wound exudate and accelerate the healing of various wounds has been used for some time. The therapeutic benefits of applying negative pressure to trauma are generally referred to as negative pressure wound therapy (NPWT). This treatment can accelerate granulation tissue formation in open traumas such as diabetic foot ulcers, dehiscent surgical wounds, and various acute and chronic wounds, supporting secondary and tertiary healing. Various specialized topical dressing systems are applied to these wounds to deliver negative pressure from a negative pressure source (Figure 1). Furthermore, internally closed surgical wounds have been treated by applying suction (vacuum) to the surgical site via internally placed drains or devices to remove wound fluid after surgery.

[0003] The applied negative pressure reduces the free volume of the wound treatment space, drawing wound exudate towards the negative pressure source, which is then drained into a reservoir or collection dressing typically located between the wound and the negative pressure source.

[0004] Negative pressure is provided to the wound treatment space by a vacuum unit or vacuum device. Vacuum devices for wound treatment face several design challenges. Vacuum devices are either disposable or reusable and ideally need to be easily portable; therefore, their components should be lightweight, energy-efficient, and preferably inexpensive.

[0005] Existing systems can be prone to occlusion by clotted blood, fibrin, adipose tissue, lost tissue debris, and wound exudate. Mechanical vacuum pumps for use in negative pressure treatment systems can also be prone to occlusion, especially in small vacuum systems. In addition, vacuum systems are typically located remotely from the wound, where it can be difficult to achieve accurate direct pressure measurement and regulation at the target site due to the potential for occlusion occurring within the mechanical vacuum pump assembly or elsewhere in the system, and due to the changing volume in the fluid collection reservoir.

[0006] Some prior art systems, such as those described in U.S. Patent Application Publication 2007 / 0179460, include pressure relief valves for controlling negative pressure in a wound. The pressure relief valves operate by introducing air into the system to prevent the applied vacuum pressure from rising above an upper threshold pressure, or by returning the system to ambient pressure. Such systems can result in a loss of negative pressure at the wound treatment site, which can adversely affect the wound healing process.

[0007] Once the system reaches the desired negative pressure, it typically remains sealed or closed off from the surrounding environment, with the only input being the exudate produced at the wound site. The system can reach equilibrium, and as a result, the wound fluid held within the system becomes still or stagnant, even if additional exudate is produced at the wound site. This still or stagnant fluid can further exacerbate blood coagulation, tissue debris settling, and fibrin formation, which can lead to an increased risk of occlusion and failure of negative pressure application at the wound. Furthermore, excessive retention of wound exudate can increase the risk of infection and edema, and may lead to biofilm formation and subsequent cessation of healing.

[0008] Further difficulties associated with negative pressure treatment include, for example, the frequent presence of elevation differences at the wound site when the patient is standing or upright. These elevation differences can lead to preferential fluid flow from the upper part of the wound, while fluid remains stagnant at the lower part.

[0009] In addition to applying negative pressure to a wound for therapeutic pressure treatment, the ability to inject fluids into and across the wound site can be useful for administering wound cleansing fluids, saline solutions, analgesics, cell suspensions, treatment solutions, and other liquid medications to inhibit bacteria or wash away the wound.

[0010] Existing vacuum devices that can also inject treatment fluids are subject to the same design limitations as standard non-administering types. These vacuum devices typically require a large amount of energy to power the pumping components within the device, which can increase the size and / or complexity of the system, due to the integrated rigid waste collection container positioned between the vacuum pump and the wound.

[0011] Treatment fluids are typically delivered to the wound via fluid supply conduits exposed to positive pressure to ensure complete saturation of the wound site, resulting in the wound site remaining at ambient or positive pressure levels. Subsequently, these systems apply a vacuum to the wound site, drawing the treatment fluid and exudate away from the wound site through a reduction in the free volume of the treatment space in response to the applied negative pressure, and the treatment fluid and exudate are then collected in an attached reservoir or collection container. The positive pressure applied to the wound treatment site can lead to unintended consequences, such as inducing leakage from the wound dressing, typically between the wound periphery and the covering dressing. The loss of vacuum pressure can also displace various elements of the specialized topical wound dressing, such as the foam porting layer / wound interface or fluid supply and exudate conduits, which can lead to short circuits in the fluid pathways through the wound. This short circuit may prevent treatment fluid delivery to the wound.

[0012] The object of the present invention is to address one or more of the aforementioned drawbacks and / or to provide at least a useful alternative for the public.

[0013] Where this specification references patent specifications, other external documents, or other sources, these references are generally intended to provide a context for considering the features of the present invention. Unless otherwise specified, references to such external documents or sources should not be construed as acknowledging that such documents or sources constitute prior art or form part of common sense in any jurisdiction. [Overview of the project]

[0014] In a first aspect, the present invention provides a system for treating wounds, which system is A fluid input unit and a fluid output unit for connection to a wound treatment device located at a wound, wherein the fluid input unit is adapted to be fluidly connected to the upstream side of the wound treatment device, and the fluid output unit is adapted to be fluidly connected to the downstream side of the wound treatment device, The air inlet valve upstream of the fluid output section, An actuator that drives the air inlet valve between an open position and a closed position, The pump downstream of the fluid input section, A motor to drive the pump and provide negative pressure to the wound treatment device, The system includes a controller that communicates with actuators and motors to operate air inlet valves and pumps, and the controller is i) Open the air inlet valve and operate the pump to maintain a first vacuum pressure in the wound treatment device and introduce air into the wound treatment device. ii) The air inlet valve is closed and the pump is operated to maintain a second vacuum pressure in the wound treatment device and remove air and fluid from the wound treatment device. The first vacuum pressure is less than or equal to the second vacuum pressure.

[0015] In a second aspect, the present invention provides a system for treating a wound, the system comprising: a fluid input and a fluid output for connection to a wound treatment device located at the wound, the fluid input being adapted to be fluidly connected upstream of the wound treatment device and the fluid output being fluidly connected downstream of the wound treatment device; an air inlet valve upstream of the fluid outlet and an actuator for driving the air inlet valve between an open position and a closed position; a treatment fluid inlet upstream of the fluid outlet for connecting a supply of treatment fluid; a treatment fluid valve between the treatment fluid inlet and the fluid outlet and an actuator for driving the treatment fluid valve between an open position and a closed position; a pump downstream of the fluid input; a motor for driving the pump to provide a negative pressure to the wound treatment device; a controller in communication with the air inlet valve actuator, the fluid valve actuator, and the motor to operate the air inlet valve, the fluid valve, and the pump, the controller being configured to: i). open the air inlet valve and operate the pump to maintain a first vacuum pressure in the wound treatment device and introduce air into the wound treatment device; ii). close the air inlet valve and operate the pump to maintain a second vacuum pressure in the wound treatment device and remove air and fluid from the wound treatment device, the first vacuum pressure being less than or equal to the second vacuum pressure; in a fluid supply state, the air inlet valve is closed; iii). open the fluid inlet valve and operate the pump to maintain a vacuum pressure in the wound treatment device and introduce treatment fluid into the wound treatment device; iv). close the fluid inlet valve and operate the pump to maintain a vacuum pressure in the wound treatment device and remove fluid from the wound treatment device.

[0016] The first or second aspect of the present invention may include any one or more of the features described in relation to the third, fourth, and fifth aspects of the present invention.

[0017] In a third aspect, the present invention provides a pump for applying negative pressure to a wound via a wound treatment device, the pump comprising: a drive mechanism; at least one flexible chamber, the drive mechanism being configured to drive the chamber to compress and expand the chamber; a pair of one-way valves in fluid communication with the chamber, the pair of one-way valves including an inlet valve for fluid flow into the chamber and an outlet valve for fluid flow out of the chamber; a pump inlet in fluid communication with at least one inlet valve; a pump outlet in fluid communication with at least one outlet valve; compression of the chamber causes fluid flow through the outlet valve and the pump outlet from the chamber, and subsequent expansion of the chamber draws fluid into the chamber through the inlet valve from the pump inlet; one inlet valve and one outlet valve each present a single orifice only within the fluid flow path through the pump from the pump inlet to the pump outlet via the inlet valve, the chamber, and the outlet valve, allowing passage of fluid and tissue debris through the valve when open.

[0018] In a fourth aspect, the present invention provides a wound treatment device for applying negative pressure to a trauma, the device comprising: >a porting component received within the trauma cavity and substantially filling the treatment space of the wound; a covering layer covering the wound; a fluid supply conduit having one or more supply conduit outlets; a fluid removal conduit having one or more removal conduit inlets; the supply and removal conduits are arranged such that the removal conduit inlet and the supply conduit outlet are in fluid communication with the porting component, and the outlet is spaced from the inlet such that fluid flow from the outlet to the inlet passes through a substantial portion of the porting component and the treatment space, and is disposed within the treatment space.

[0019] In a fifth aspect, the present invention provides a portable vacuum unit for a wound treatment system for providing negative pressure treatment to a wound, the vacuum unit being Air inlet valve, An actuator that drives the air inlet valve between an open position and a closed position, A pump including a pump inlet and a pump outlet, A motor to drive the pump, A controller that communicates with actuators and motors to operate air inlet valves and pumps to apply negative pressure treatment to wounds, It includes an interface manifold, and the interface manifold is A first fluid passage having a first inlet and a first outlet, wherein the first inlet is connected to an air inlet valve and the first outlet provides a vacuum unit fluid outlet for connection to the upstream side of a treatment device, and A second fluid passage having a second fluid inlet and a second fluid outlet, wherein the second outlet is connected to a pump inlet and the second inlet provides a vacuum unit fluid inlet for connection to the downstream side of a treatment device. Includes an air inlet valve, actuator, pump, motor, controller, and housing for the interface manifold, The interface manifold is a separate assembly within the housing that provides an interface between the air inlet valve and the upstream side of the wound treatment device, and an interface between the pump inlet and the downstream side of the wound treatment device.

[0020] Further features of the above aspects of the present invention are described in the appended claims.

[0021] definition In this specification and in the claims, unless the context indicates otherwise, the term “exudate” is intended to mean any fluid removed from a patient’s wound site. Exudate may include exudate produced by the patient and / or fluid applied to the wound site by a system including a treatment fluid such as air, saline solution, or a drug-providing fluid, or fluid obtained through a surgical intervention that can introduce or administer a treatment fluid to the wound site via a separate route such as injection.

[0022] In this specification and in the claims, unless the context indicates otherwise, the terms “fluid” and “treatment fluid” are intended to mean liquid fluids such as wound cleansing solutions and liquid treatment fluids. Therefore, unless the context suggests otherwise, the terms “fluid” and “liquid” may be used interchangeably.

[0023] In this specification and in the claims, the terms “negative pressure” and “vacuum pressure” may be used interchangeably to mean gauge pressure below atmospheric pressure and absolute pressure below atmospheric pressure, and may also be referred to as pressure below atmospheric pressure or suction pressure. For example, a negative pressure or vacuum pressure of 100 mmHg is a gauge pressure of -100 mmHg or an absolute pressure of approximately 660 mmHg. The terms “high,” “increasing,” or other similar terms used in relation to negative pressure or vacuum pressure are intended to mean higher or increasing negative pressures, for example, a gauge pressure of -150 mmHg (610 mmHg absolute) may be described as “higher” than a gauge pressure of -100 mmHg (660 mmHg absolute). Similarly, with respect to the terms “low,” “decreasing,” or other similar terms used in relation to negative pressure or vacuum pressure, a gauge pressure of -100 mmHg may be described as “lower” than a gauge pressure of -150 mmHg.

[0024] In this specification and in the claims, unless the context indicates otherwise, the term “NPT” is intended to mean negative pressure treatment (NPT) relating to a system or apparatus configured to provide treatment to any internal or external wound by applying “negative pressure” or “vacuum pressure.” For the purposes of clarity, a system configured to provide negative pressure wound treatment to a wound is considered a type of negative pressure treatment system, as is a system configured to apply suction to an internal, closed surgical site.

[0025] The present invention can also be broadly said to consist of the parts, elements, and features that are referred to or shown individually or collectively in this specification, and any combination of any two or more such parts, elements, or features, or any combination of all of them. Where any particular integer having equivalents known in the art to which the present invention relates is referred to herein, such known equivalents shall be deemed to be incorporated herein as if they were described individually.

[0026] As used herein and in the claims, the term “contains” means “consisting of at least part of.” When interpreting any description in this specification and in the claims that contains the term “contains,” other features that do not begin with this term may also exist. Related terms such as “contains” and “included” are interpreted similarly.

[0027] References to numerical ranges disclosed herein (e.g., 1 to 10) are intended to also incorporate references to all rational numbers within that range and to any range of rational numbers within that range (e.g., 1 to 6, 1.5 to 5.5, and 3.1 to 10). Accordingly, all subranges of all ranges expressly disclosed herein are expressly disclosed herein.

[0028] As used herein, the term "(plural)" following a noun means the plural and / or singular forms of that noun. As used herein, the term "and / or" means "and" or "or," or both, where the context allows. [Brief explanation of the drawing]

[0029] Herein, the present invention will be described only by reference to the accompanying drawings. [Figure 1] This is a schematic diagram of a prior art negative pressure treatment system configured for treating trauma. [Figure 2] This specification provides a high-level schematic diagram of a negative pressure treatment (NPT) system according to at least one embodiment described herein. [Figure 3] Figure 2 illustrates the system applied to trauma. [Figure 4] Figure 2 illustrates the system applied to internal injuries. [Figure 5] Figure 2 is a schematic diagram of the vacuum unit of the system. Figures 5(ii) and 5(iii) are schematic cross-sectional views of the double-lumen conduit along planes A and B in Figure 5(i). [Figure 6] Figure 2 is a schematic diagram of the system. [Figure 7] Figure 2 is a further schematic diagram of the system, equivalent to the schematic diagram in Figure 6, but additionally illustrating additional components of the system's vacuum unit. [Figure 8] This is a schematic diagram of an alternative embodiment of the NPT system having the system features of Figure 2 and additionally including a treatment fluid reservoir. [Figure 9] Figure 8 is a schematic diagram of the system. [Figure 10] Figure 8 is a further schematic diagram of the system, equivalent to the schematic diagram in Figure 9, but additionally illustrating additional components of the system's vacuum unit. [Figure 11] This is a schematic diagram of a further alternative embodiment of the NPT system. [Figure 12]This is a further schematic diagram equivalent to the schematic diagram in Figure 11, but it additionally illustrates additional components of the system's vacuum unit. [Figure 13] Two diagrams of a pump for use in NPT systems, such as the NPT system described herein, are provided. [Figure 14] Figure 13 is a cross-sectional view of the pump. [Figure 15] Figure 13 is an exploded view of the pump. [Figure 16] This is another exploded view of the pump shown in Figure 13. [Figure 17] Figure 13 illustrates the pump with an interface manifold that is detachably attached to the pump inlet, corresponding to the systems in Figures 11 and 12. The manifold can also be adapted for use with the systems in Figures 9 and 10. [Figure 18] Figure 17 illustrates the pump and interface manifold, with the interface manifold separated from the pump. [Figure 19] Figures 17 and 18 illustrate an interface manifold. [Figure 20] Figures 17 to 19 provide two diagrams of an interface manifold that is nearly identical to the interface manifold shown. [Figure 21] This is a cross-sectional view of the manifold of Figure 20, having a cross-section passing through the manifold shown in the end view presented in the figure. [Figure 22] This is another cross-sectional view of the manifold of Figure 20, having a cross-section passing through the manifold shown in the end view presented in the figure. [Figure 23] Figure 20 is an exploded view of the manifold. [Figure 24] Figures 6 and 7 illustrate alternative interface manifolds corresponding to the systems shown. [Figure 25] Figure 24 is an exploded view of the manifold. [Figure 26]This is a cross-sectional view of the manifold of Figure 24, having a cross-section passing through the manifold shown in the end view presented in the figure. [Figure 27] This example illustrates an alternative pump, along with a motor to drive it. [Figure 28] Figure 27 is an exploded view of the pump. [Figure 29] This is an end view of a duckbill valve that may be incorporated into the pump assembly described herein. [Figure 30] Figure 29 is a cross-sectional view through the duckbill valve. [Figure 31] This shows a cross-section of a double-lumen conduit. [Figure 32] A cross-section of an alternative double-lumen conduit is shown. [Figure 33] Figures 5 to 7 provide front and side views of the portable vacuum unit of the system. [Figure 34] Figure 33 provides a partially exploded view of the vacuum unit to illustrate the interface manifold in Figure 24. [Figure 35] Figure 33 provides an exploded view of the vacuum unit. [Figure 36] Figure 33 shows a vacuum unit with the top cover of the unit's enclosure or housing removed, revealing the assembled components of the unit inside the enclosure. Wiring and tubing connections are omitted for clarity. [Figure 37] Figures 11 and 12 provide front, side, and rear views of the portable vacuum unit of the system. [Figure 38] Figure 37 provides a rear view and a partially exploded view of the unit, with the rear cover of the unit's housing or casing removed, revealing the interface manifold shown in Figure 19. [Figure 39] Figures 8 to 12 are schematic diagrams of the system, including the trauma treatment device. [Figure 40] Figure 39 is a cross-sectional view of a wound treatment device illustrated. [Figure 41]Figure 40 shows the arrangement of supply and removal conduits provided with porting components in a trauma treatment device, as shown. [Figure 42] Figure 40 shows another supply and removal conduit arrangement provided with porting components in a trauma treatment device. [Figure 43] This illustrates various flow characteristics when air is mixed into a liquid flow. [Figure 44] This specification shows the system architectures of various embodiments of the NPT system described herein. [Figure 45] This specification shows the system architectures of various embodiments of the NPT system described herein. [Figure 46] This specification provides high-level control flow diagrams for various embodiments of the NPT system described herein. [Figure 47] The control flow diagrams for the airflow state in Figures 46 and 51 are provided. [Figure 48] The control flow diagrams for the pressurized state in Figures 46 and 51 are provided. [Figure 49] Figure 46 provides a control flow diagram for the holding pressure state in the control flow diagram. [Figure 50] The control flow diagrams for the timeout state in Figures 46 and 51 are provided. [Figure 51] This specification provides high-level control flow diagrams for various embodiments of the NPWT system described herein. [Figure 52] A control flow diagram for the holding pressure state in the control flow diagram of Figure 51 is provided. [Figure 53] Figure 51 provides a control flow diagram for the fluid flow state in the control flow diagram. [Figure 54] Figure 53 provides a control flow diagram for the flushing cycle of the fluid flow state. [Figure 55] This provides a chart showing the system performance of the treatment system test setup. [Figure 56]This is a schematic diagram of another treatment system that includes both internal and external trauma treatment devices. [Figure 57] Figure 56 is a schematic diagram of the system. [Figure 58] Figures 56 and 57 provide high-level control flow diagrams of various embodiments of the NPT system. [Figure 59] A control flow diagram for the pressurization state in the control flow diagram of Figure 46 or Figure 58 is provided. [Figure 60] The control flow diagrams for the holding state in Figures 46 and 58 are provided. [Figure 61] A control flow diagram for the airflow state in the control flow diagram of Figure 46 or Figure 58 is provided. [Figure 62] A control flow diagram for the timeout state in the control flow diagram of Figure 46 or Figure 58 is provided. [Figure 63] A control flow diagram for the dressing pressure state in the control flow diagram of Figure 46 or Figure 58 is provided. [Modes for carrying out the invention]

[0030] In the figures, the same reference numerals are used for different embodiments to illustrate similar features.

[0031] Figures 2 to 12, Figure 39, and Figures 56 and 57 illustrate exemplary embodiments of negative pressure treatment systems (referred to herein as treatment systems) for removing fluid from a wound, or for supplying treatment fluid to a wound and removing fluid from the wound.

[0032] Referring to Figure 2, at a general level, the treatment system 100 comprises a wound treatment device 3 located at a wound treatment site ("wound") 4, a vacuum pressure unit 2 having a vacuum pump assembly (e.g., pump assembly 15 in Figure 5) for applying negative pressure to the wound 4 via the treatment device 3, and a fluid collection reservoir 6 for collecting fluid returned from the wound 4.

[0033] The vacuum pressure unit (or vacuum unit) 2 is configured to position the pump assembly 15 upstream of the fluid collection reservoir 6 and downstream of the wound treatment device 3. The wound treatment device 3 may comprise a locally applied wound dressing (Figure 39), an implanted treatment device, or a combination of both in a combined configuration (Figure 56). The fluid collection reservoir 6 is configured to include one or more air-permeable filters or vents 6a to maintain the fluid collection reservoir 6 and connected conduits 5c at ambient pressure levels.

[0034] The vacuum unit 2 is fluid-coupled to the wound treatment device 3 via at least one conduit. The conduit from the vacuum unit 2 to the wound treatment device 3 may comprise a bipartite conduit having a first conduit 5b extending from the vacuum unit 2 and a second conduit 5a extending from the wound treatment device 3. The second conduit may be part of the wound treatment device 3 or may be connected to the treatment device 3 by a connector (not shown). A connector 7 is provided for fluid-coupled the first conduit 5a and the second conduit 5b. Alternatively, a continuous conduit may extend between the vacuum unit 2 and the treatment device 3.

[0035] A topically applied dressing for use in negative pressure wound treatment includes a substantially air-impermeable and liquid-impermeable occlusion layer that covers and adheres to the wound or incision to seal the wound site for the application of negative pressure. Typically, the conduit 5a extends from the dressing, but alternatively, the dressing may have a connector for receiving a conduit from the vacuum unit 2, or the occlusion layer may simply cover, adhere to, and seal the conduit.

[0036] The connector 7 may include a one-way valve oriented to allow fluid flow from the wound 4 toward the vacuum unit 2 and to prevent backflow of fluid from the pump toward the wound. In an alternative embodiment, the one-way valve may instead be provided within the vacuum unit 2, elsewhere on the conduits 5a, 5b, or as part of the treatment device 3. In a further alternative example, the treatment system 100 may not have a one-way valve between the treatment device 3 and the vacuum unit.

[0037] In some embodiments, the conduit between the vacuum unit 2 and the treatment device 3 may comprise a double-lubricated conduit with a main lumen and a secondary lumen for the passage of fluid flowing from the wound to the pump assembly 15. The secondary lumen may allow for the measurement of pressure at the wound site. The secondary lumen provides for the delivery of air and / or treatment fluid to the wound 4. However, in alternative embodiments, multiple conduits, each having a single lumen, may be provided between the vacuum unit 2 and the treatment device 3.

[0038] A further conduit 5c for fluid coupling the pump assembly 15 to the reservoir 6 is provided between the vacuum unit 2 and the reservoir 6. A connector 8 may be provided for fluid coupling the conduit 5c to the reservoir 6.

[0039] In a preferred embodiment, the vacuum unit 2 is a portable handheld unit. The vacuum unit 2 may be a single-use unit intended for use on one patient. In an alternative embodiment, the vacuum unit 2 may be configured for use on multiple patients. The vacuum unit 2 comprises a (plastic) shell or housing for housing the pump assembly 15 and other components. The vacuum unit 2 comprises a user interface 14 for operating the vacuum unit 2. The user interface may include controls for turning the pump assembly 15 of the system 100 on and off, and may allow the operator to control parameters of the pressure treatment applied to the wound 4, such as the level of vacuum pressure being applied, or the length, size, and frequency of pressure oscillations between an upper and lower setpoint.

[0040] In an alternative embodiment, the user interface 14 may also include controls for remotely connecting a monitoring device to the vacuum unit and transmitting data to a system operator or user to assist in monitoring the procedure.

[0041] Figure 3 illustrates the system 100 of Figure 2 used with a dressing or trauma treatment device 30 for an open leg wound. However, the system 100 is also suitable for use on internal wound sites, as illustrated in Figure 4. Figure 4 illustrates an internal wound site located on the patient's chest, but the system may be used to treat internal wounds located in other areas, for example, to treat an abdominal wound.

[0042] Referring here to Figures 5(i) to 5(iii) in conjunction with Figure 2, the vacuum unit 2 comprises a vacuum pump assembly 15, which is described in more detail below, a battery (16 in Figure 7) or other power source, a vacuum unit connector 9 which is in fluid communication with conduits 5b, 5a for delivering and receiving fluid from the wound treatment site 4, and a vacuum unit outlet connector 10 which is in fluid communication with conduit 5c to the reservoir 6 for fluid flow from the pump assembly 15 to the reservoir 6. The connectors 9, 10 are configured to connect to the ends of the respective conduits 5b, 5c and may be in any preferred form, for example, these connectors may include Luer type connectors.

[0043] In one embodiment, the vacuum unit connector 9 may comprise two one-way valves such that the one-way valve in the sub-connector 9b is oriented to allow fluid flow from an upstream source, such as ambient air that has passed through a sterile filter (filter 19 in Figure 6), or from a treatment fluid reservoir (reservoir 26 in Figure 8), to the wound 4. The corresponding one-way valve in the main connector 9a is oriented to allow fluid flow from the wound 4 toward the vacuum unit 2. In some embodiments, the one-way valves in the main connector 9a and sub-connector 9b may be configured to close when the vacuum unit connector 9 is disconnected from the vacuum unit 2. These valves are then opened to allow fluid passage when the connected vacuum unit 9 is reconnected to the vacuum unit 2. Examples of known prior art connectors having such features include needleless or non-needed connectors for use in IV applications, such as the BD® MaxPlus® needleless connector, which only allows fluid passage when engaged with a suitable Luer locking connector.

[0044] The conduit 5b for fluid flow in and out of the vacuum unit connector 9 is a double-lubricated conduit having a main lumen 11 and a secondary lumen 12. The connector 9 includes a main connector 9a providing a fluid inlet for connection to the main lumen 11 and a secondary connector 9b providing a fluid outlet for connection to the secondary lumen 12, while keeping the flow from these lumens isolated. The larger main lumen 11 allows the passage of fluid flowing from the wound through the main connector to the vacuum pump assembly 15. The secondary connector or supply connector 9b may be separated from the main connector or removal connector 9a.

[0045] The main lumen 11 and secondary lumen 12 are preferably provided as adjacent passages within a single body / conduit along most of the length of these lumens, as illustrated in the cross-sectional view of Figure 5(iii) along the cutting line B of Figure 5(i). However, adjacent to the vacuum unit 2 and / or the wound treatment device 3, the double-lumen conduits 5a, 5b may be divided or separated into two separate rims or conduits, as shown in the cross-sectional view of Figure 5(ii) along the cutting line A of Figure 5(i): a supply conduit with a secondary lumen 12 and a removal conduit or exudate conduit with a main lumen 11, for ease of connection to the vacuum unit 2 and / or to allow the supply conduit to enter the wound or wound treatment device 3 at a different location from the removal conduit.

[0046] The supply conduit 12 is in fluid communication with the pressure sensor Pv, enabling the measurement of pressure upstream of the wound treatment device 3.

[0047] The vacuum unit 2 includes an air inlet valve 18 that communicates with the supply conduit 12. The air inlet valve 18 is controlled to introduce air into the treatment system 100 to assist in lifting the fluid from the wound site 4, as described in more detail below.

[0048] As shown in Figure 5(i), the air inlet valve 18 may have an inlet for drawing ambient air into the system from outside the vacuum unit 2 housing. Alternatively, the inlet of the air inlet valve may draw air from inside the vacuum unit housing / enclosure.

[0049] A sterile filter 19 is provided to prevent biological contamination and the entry of non-sterile air into the system 100 and the wound site 4. In Figure 5(i), the filter 19 is provided at the inlet of the air inlet valve 18, but the filter may be located elsewhere between the air inlet valve 18 and the vacuum unit fluid supply connector 9b, or between the air inlet valve 18 and the wound site 4.

[0050] Figure 6 provides a more detailed schematic illustration of the treatment system 100. The boundary or outer housing of the vacuum unit 2 is illustrated by dashed lines in Figure 6. Upstream of the treatment device 3, the vacuum unit 2 comprises an air inlet valve 18, optionally a pressure sensor Pv, and a sterilization filter 19. Downstream of the treatment device 3, the vacuum unit 2 comprises a pump assembly 15, and optionally a pressure sensor Pp between the pump assembly 15 and the treatment device 3. The vacuum unit 2 may also comprise a connection manifold 20 that provides a connection interface between the conduits 5a, 5b to the treatment device 3 and the vacuum unit 2. The connection manifold 20 is illustrated by dotted lines in Figure 6 and dashed lines in Figure 7, and replaces the connector 9 shown in Figure 5. The manifold is described in more detail below.

[0051] Figure 7 provides a further schematic diagram of a treatment system 100 equivalent to that in Figure 6, but additionally illustrates a vacuum unit 2 comprising a power supply (in the form of a battery or battery pack 16), a user interface 14, a controller 17, and a drive motor 13 for driving a pump assembly 15. The motor, pressure sensors Pv, Pp, and actuators (not shown) for driving an air inlet valve 18 communicate electrically with the controller 17. In this embodiment, the pump controller 17 includes either a shortwave or longwave form of wireless transmission via preferred electronic components known to those skilled in the art.

[0052] Figures 8 to 12 illustrate further embodiments of a treatment system for supplying fluid to a wound and removing fluid from a wound. The embodiments in Figures 8 to 12 include the same or similar features as the system 100 described above with reference to Figures 2 to 7, but are additionally configured to provide treatment fluid to the wound treatment device 3.

[0053] Referring to Figures 9 to 12, the vacuum unit 2 may have one or more ports 25 for receiving treatment fluid for delivery to the wound site. The ports 25 are preferably configured to be nominally closed to the fluid passage when disconnected from the treatment fluid reservoir 26, which is then opened when engaged with a Luer connector. B. Braun Medical® CARESITE® connectors provide an example of such ports.

[0054] A therapeutic agent in the form of a treatment fluid can be selectively delivered to the wound treatment device 3 via a supply conduit 12. The fluid source or treatment fluid reservoir 26 may be connected to the fluid port 25 of the vacuum unit 2 via a conduit or connection to an intravenous (IV) fluid administration set, such as, for example, a Baxter® EMC 9608 Admin Set, a B. Braun Medical® Single Chamber IV Infusion Set, or a similar sterile IV infusion treatment set. The treatment fluid reservoir is preferably at atmospheric pressure while connected to the treatment system. This can be achieved by using a non-permeable IV infusion treatment set in combination with a flexible fluid bag, such as a Baxter® Sodium Lactate (Hartmann or Composite Sodium Lactate) IV Bag, or by connecting a permeable IV infusion treatment set to a rigid or semi-rigid container of the treatment fluid, such as B. Braun Medical® Prontosan® Wound Cleansing Solution.

[0055] Examples of therapeutic fluids include, but are not limited to, sodium lactate compounds, physiological saline (0.9% NaCl - sodium chloride), and 0.45% normal physiological saline (0.45NaCl). Antimicrobial agents and solutions may also be applied to the treatment of infections and may contain agents such as polyhexanide (PHMB), silver nitrate, hypochlorous acid (HOCl), sodium hypochlorite, betaine, sodium hypochlorite, superoxidized water at neutral pH, or any other antimicrobial wound irrigation solution.

[0056] Other treatment fluids may also include cell suspensions and cell-based fluids for promoting wound healing. The fluids may include fluid gels derived from the ECM and mixed with water for injection, hyaluronic acid, growth factors to aid healing, analgesics such as fentanyl or morphine for pain relief, and anti-inflammatory agents such as ketorolac or diclofenac, but other fluids are conceivable and will be apparent to those skilled in the art.

[0057] Infusion of autologous or allogeneic cell-based therapies containing platelet-rich plasma, stem cells, stromal cells, keratinocytes, lymphocytes, bone marrow aspirate, serum, or dendritic cells may aid in wound repair and healing.

[0058] Intravenous administration of chemotherapy drugs can also be used to assist in the local treatment of cancerous cells that may not be surgically treatable, or as part of an overall treatment plan after the resection of cancerous tissue.

[0059] Referring to Embodiment 200 in Figures 9 and 10, the treatment fluid inlet valve 22 is selectively operable to allow fluid to flow from the treatment fluid reservoir 26 into the supply conduit 12 leading to the wound. The fluid reservoir is at atmospheric pressure. When the treatment fluid inlet valve 22 is selectively opened, the negative pressure from the pump assembly 15 applied to the wound 4 via the removal conduit 11 acts to draw fluid from the treatment fluid reservoir 26 toward the dressing or wound treatment device 3. When the treatment fluid inlet valve 22 is operated, a controller in the vacuum unit 2 (not shown in this figure) detects the subsequent drop in the vacuum pressure level in the Pv and / or Pp pressure sensors and operates the pump assembly 15 to maintain the vacuum pressure at a target level. The control algorithm is described in more detail below. In the illustrated embodiment, an air inlet valve 18 and a sterile filter 19 are provided upstream of the treatment fluid valve 22.

[0060] In the embodiment 300 shown in Figures 11 and 12, the system does not have a treatment fluid inlet valve 22. The system 300 may include an orifice or other flow limiter to control the amount of treatment fluid introduced into the system during negative pressure treatment. In one embodiment, the administration of treatment fluid is controlled via the use of an intravenous (IV) fluid administration set, such as a Baxter® EMC 9608 Admin Set, a B. Braun Medical® Single Chamber IV Infusion Set, or a similar sterile IV infusion treatment set, connected to unit 2 via a fluid port 25. The fluid flow rate of the treatment fluid introduced into the supply conduit 12 is controlled via a roller clamp in the set, which is adjusted to change the flow limit in a section of the tube interfaced with the roller clamp component. In this embodiment, the fluid drip rate may be visually checked via the drip chamber of the IV infusion set when the chamber is oriented upright, and any further flow adjustments are made via roller clamp adjustment. This embodiment provides a manual means for introducing treatment fluid into a wound 4 via a wound treatment device 3.

[0061] In an alternative embodiment, the vacuum unit 2 may be connected to an infusion pump via a fluid port 25 to allow fluid to be supplied to the wound treatment device 3 in a selectable and controllable manner. Such an infusion pump system may include, for example, a B. Braun Medical® Vista® basic high-volume infusion pump or a BD® Alaris® Syringe Module, which can controllably deliver treatment fluid at a rate of 0.1 ml / hour to 1200 ml / hour, either intermittently or continuously. These systems typically propose means for selecting the volume, flow rate, and frequency at which the treatment fluid is dispensed. When the treatment fluid is introduced into the vacuum unit 2, the system detects a subsequent drop in the set vacuum pressure level using Pv and / or Pp pressure sensors and activates the pump assembly 15 to maintain the system's target level of vacuum pressure. The control algorithm is described in more detail below.

[0062] In the embodiments shown in Figures 8 to 12, the vacuum unit 2 includes a connection manifold 21 that provides connection interfaces between the vacuum unit 2 and conduits 5a, 5b to the treatment device 3 via fluid ports 25, and between the vacuum unit 2 and the treatment fluid reservoir 26. The connection manifold 21 is illustrated by dotted lines in Figures 9 to 12 and replaces the connector 9 shown in Figure 8. The manifold is described in more detail below.

[0063] In the system 300 of the embodiments shown in Figures 11 and 12, the vacuum unit 2 additionally includes a color sensor 24 electronically connected to the vacuum unit controller 17. In this embodiment 300, the color sensor 24 is positioned along a fluid path located between the outlet of the pump 15 and the outlet connector 10. However, the color sensor may alternatively be positioned along the fluid path at any preferred location upstream of the inlet of the pump 15.

[0064] The color sensor 24 may be useful for detecting color changes in the wound exudate flowing from the treatment device 3 through the system at the wound site 4. For example, the natural color change from the initial blood-rich wound exudate immediately after surgery to the pink color of serous blood-like drainage (blood and serum) and / or clear serous drainage (serum only). This operation of the color sensor 24 can be enhanced by supplying filtered air from upstream of the treatment device 3. The filtered air displaces the fluid for a short time frame, similar to the case of direct aspiration of fluid from the treatment site 4 via a needle, to produce a readable sample of the fluid.

[0065] Inclusion of a color sensor within the system of various embodiments for supplying and removing treatment fluid from a wound may offer further advantages. For example, the color sensor 24 may be configured to detect the passage of treatment fluid supplied from the treatment fluid reservoir 26, through the upstream fluid path, removal conduit 11, wound treatment device 3, and supply conduit 12 to the vacuum unit 2, and to indicate complete saturation of the treatment fluid through the connected system. In other embodiments, the treatment fluid may be combined with a color-based indicator for detecting changes in the wound in response to the presence of infection, biofilm, or other wound-based lesions.

[0066] The treatment system 400 in the embodiments of Figures 56 and 57 is similar to embodiment 100 in Figure 6, but includes an additional control valve 29 for coupling to a secondary wound treatment device. The control valve 29 is coupled to the inlet of the pump 15 and is in fluid communication with this inlet. In the configuration shown in Figure 57, the trauma treatment device 30 is connected to the vacuum unit 2 via a manifold 20 and a further fluid conduit 32 to a main lumen 11 that connects the primary wound treatment device 3 to the outlet of the pump 15. In embodiment 400, the vacuum unit 2 includes a dressing port 31 for connecting the trauma treatment device 30 to the inlet of the pump 15 via the conduit 32. The supply of vacuum pressure to the trauma treatment device 30 is controlled via an actuator of the dressing pressure control valve 29.

[0067] In the embodiment 400 shown in Figure 57, the system controller 17 is connected to a dressing pressure sensor Pd located upstream of the pump 15 and the dressing pressure control valve 29 and downstream of the dressing port 31, and the controller is configured to supply vacuum pressure from the pump 15 to the wound treatment device 30. The system controller in this embodiment is described in more detail below.

[0068] Here, we will describe the various components of treatment systems 100, 200, 300, and 400.

[0069] reservoir As described, the treatment systems 100, 200, 300, and 400 include a reservoir 6 for collecting fluid removed from the wound site 4, such as wound exudate. In a preferred embodiment, the reservoir 6 is located furthest from the wound and therefore downstream of the pump assembly 15 to collect fluid removed from the wound after passing through the pump assembly 15.

[0070] In the embodiment shown, the reservoir 6 includes a flexible bag. Alternatively, a rigid reservoir may be provided.

[0071] The reservoir 6 comprises one or more air-permeable filters or vents 6a provided in the wall of the reservoir, for example, a hydrophobic vent provided covering an aperture of an impermeable membrane. The air-permeable filters or vents allow gas to pass through, thereby preventing a pressure rise in the reservoir that would hinder effective pumping. An exemplary reservoir has eight vents 6a, each having a diameter of 8 mm and a pore size of 3 microns to maintain a high level of airflow through the system.

[0072] Blood clots, fibrin, and other coagulated fluids or tissue debris can block the vent membrane, causing the bag to inflate with air introduced into the fluid channel. This inflation may cause the bag to rupture and leak fluid, or it may prevent the pump from generating the required vacuum pressure by forcing the outlet valve open under excessive positive pressure.

[0073] To avoid these problems, highly salt-compatible sodium polyacrylate polymers, or other equivalent blood-compatible superabsorbent polymers, may be added to the reservoir to coagulate the blood and wound fluid in the bags. These polymers are available as free particles, particles suspended in a soluble PVA film pouch, or polymers suspended in a textile / cloth-like medium. In the embodiment shown in Figure 56, the reservoir 6 is shown to comprise two bags of absorbent polymer 33.

[0074] The use of this polymer in conjunction with one or more vents on the bag prevents the bag from expanding and allows the fluid channels of the treatment system to handle much more air as it is introduced into the system.

[0075] Pump Assembly Here, the vacuum pump assembly 15 will be described with reference to Figures 13 to 16. The pump assembly 15 is driven by a motor 13, as illustrated in Figures 7, 10, and 12. The pump assembly 15 comprises a swash plate 52, a plurality of flexible chambers 53 (diaphragms), a plurality of pairs of flexible valves 54, 55, each pair of which is in fluid communication with its respective flexible chamber 53, and a pump inlet 56 and outlet 57.

[0076] Pump cover / Inlet / Outlet The pump inlet 56 and outlet 57 are provided on the pump cover 58. In the shown embodiment, the inlet 56 and outlet 57 are provided side by side on the pump cover 58, with the inlet 56 located closer to the edge of the pump cover 58 and the outlet 57 located closer to the center of the pump cover 58.

[0077] Each of the inlet 56 and outlet 57 is provided with an aperture that extends through the pump cover for the passage of fluid into and out of the pump. Referring to the exploded view in Figure 16, the lower side of the pump cover 58 is provided with two channels, namely, an (outer) inlet channel 61 surrounding an (inner) outlet channel 62. The aperture from inlet 56 opens into the inlet channel 61 so that fluid flowing into the pump through inlet 56 flows into the inlet channel 61. The aperture from outlet 57 opens into the outlet channel 62 so that fluid flowing out of the pump flows into the outlet channel 62 and out through outlet 57.

[0078] The inlet channel 61 and the outlet channel 62 are distinct and are fluidically separated so that fluid cannot flow directly from one channel to the other.

[0079] valve Referring to Figures 14 to 16, the pump is equipped with two pairs of valves, each valve pair corresponding to and position-aligned with each chamber 53. Each valve pair consists of an inlet valve 54 and an outlet valve 55. The valve support components position the inlet valve 54 position-aligned with the inlet channel 61 so that fluid from the inlet channel is in fluid communication with the inlet valve 54. Each outlet valve 55 is positioned to be position-aligned with and in fluid communication with the outlet channel 62 so that fluid from the outlet valve 55 flows into the outlet channel 62.

[0080] Valves 54 and 55 are one-way valves that allow fluid to pass through the valve in one direction and prevent fluid from flowing through the valve in the opposite direction. In each valve pair, the inlet valve 54 and outlet valve 55 are oriented opposite each other so that fluid can only flow into the corresponding chamber 53 through the respective inlet valve 54 and out of the chamber 53 through the respective outlet valve 55.

[0081] Valves 54 and 55 each feature an elastic "duckbill" type valve. Each of these duckbill valves has two walls inclined in opposite directions, with a single slit-type opening at the ends of the two walls. Under pressure from the fluid between the two walls, the slit is forced open as the two walls separate, allowing the fluid to flow through the valve.

[0082] Referring to Figures 29 and 30, in some embodiments, each flexible valve 54, 55 may be provided with a number of reinforcing ribs 59 on the downstream surface of the inclined wall. These ribs 59 help maintain the valve shape under back pressure and reduce the possibility of the valve collapsing, bending, or inverting under back pressure, which may otherwise affect thin-walled flexible valves. The ribs 59 provide rigidity to the wall without hindering the bending and opening of the valve under flow. In the embodiments shown, the ribs have a substantially triangular cross-section, but in alternative embodiments, these ribs may have other shapes. The reinforcing ribs may also reinforce the valve to reduce the occurrence of reverse leakage through the valve.

[0083] Referring to Figures 13 to 16, the valves 54 and 55 are supported within a valve housing 63. The valve housing comprises two parts 64 and 65. The two parts are fixed to each other, holding the valves 54 and 55 between the two parts 64 and 65. Each part of the valve housing can be described as a valve support component. The flange portions of the valves 54 and 55 are compressed between the two valve housing parts 64 and 65 to provide a seal and prevent leakage. The valve housing 63 supports the valves 54 and 55 such that the inlet valve 54 is in fluid communication with the inlet channel 61, the outlet valve 55 is in fluid communication with the outlet channel 62, and the valves 54 and 55 are arranged in pairs to correspond to a single chamber 53 as described above.

[0084] The valve housing 63 is fixed to the pump cover 58, thereby fluid-sealed by the pump cover, separating the inner channel 61 and the outer channel 62, and thus the pump inlet 56 and outlet 57. For example, a portion 64 of the valve housing 63 is ultrasonically welded to the pump cover 58. The entire pump assembly 15 is then fastened together using screws, clamping the valves 54, 55 within the valve housing 63.

[0085] The pump assembly 15 includes a fluid passage through the pump from the pump inlet 56 to the pump outlet 57 via an inlet valve 54, a chamber 53, and an outlet valve 55. In the illustrated embodiment, the inlet valve 54 and the outlet valve 55 each present a single orifice in the passage when open.

[0086] As described above, in a preferred embodiment, the exudate reservoir 6 is located downstream of the pump assembly 15. This means that fluid from the wound passes through the pump assembly 15. Valves 54, 55, which present a single orifice, reduce the risk of blockage in the pump assembly 15 caused by debris such as tissue debris, fibrin, blood clot, loose connective tissue, and adipose (fatty) tissue returned from the wound 4 passing through and blocking the vacuum pump assembly. Other valve types, such as umbrella valves, have multiple smaller apertures and are therefore more prone to blockage in the valve.

[0087] Each single orifice of valves 54, 55 has an area similar to or greater than the minimum area of ​​the fluid flow path from the pump inlet 56 to the pump outlet 57 when the valve is open. Preferably, the opening area of ​​each single orifice of valves 54, 55 is greater than or equal to the area of ​​the pump inlet 56. Therefore, if an obstruction occurs in the pump assembly, it occurs at the pump inlet 56 rather than at a point inside the pump assembly. Preferably, the opening area of ​​the single orifice is greater than the cross-sectional area of ​​the lumen of the supply conduit 11.

[0088] The illustrated embodiments include duckbill valves 54, 55. However, other valves presenting a single large orifice to the pump flow path are possible, such as flapper valves, squapper valves, check valves, cross-slit valves, and dome valves. However, valves consisting of a single, integrated flexible member are preferred. The valves are preferably molded from liquid silicone rubber (LSR) to reduce the possibility of wound proteins such as fibrin binding to the valve.

[0089] In the illustrated embodiment, the valve housing 63 includes a through port 66 having opposing spigots for attaching a hose to conveniently secure a fluid lumen separated from the fluid passage through the pump assembly 15. The through port 66 and spigots may be provided elsewhere on the pump assembly, for example as part of the pump cover 58, or the pump assembly may not have a through port and spigots. The illustrated embodiment includes a port 71 for connecting a pressure sensor (Pp), for example via a tube, to measure the pressure in the pump inlet channel, indicating the system pressure downstream of the treatment device.

[0090] In other embodiments, port 71 may be configured to connect a control valve, such as the dressing control valve 29 in Embodiment 400 of Figures 56 and 57, to the pump inlet to supply vacuum pressure to the secondary wound treatment device 30. Alternatively or additionally, the pump cover 58 may include one or more further ports 71 to facilitate connection to pressure sensors and valves.

[0091] Cylinder / Piston Swashplate Each pair of valves 54, 55 is in fluid communication with its respective flexible chamber 53. The illustrated embodiment comprises two chambers 53 corresponding to two pairs of valves 54, 55. However, alternative embodiments may have a single chamber or three or more chambers. Preferably, the pump assembly 15 comprises two or more chambers 53 and associated pairs of valves 54, 55 such that one chamber is always compressed and the other is always expanded.

[0092] In the illustrated embodiment, the chamber 53 is provided as a single, integrated component. The component includes a flexible, elastic, and air-impermeable material such as silicone. The chamber housing 67 supports and houses the chamber component and is attached to the valve support housing 63 to hold the chamber 53 in a positional alignment with the respective valves 54, 55.

[0093] The flexible chamber 53 is substantially cylindrical. Each chamber is provided with an associated connector 68 that protrudes from the bottom of the chamber 53 and is movable axially (along the axis of the cylinder) to compress and expand the chamber 53.

[0094] In the illustrated embodiment, the connector 68 is connected to the swash plate 52, which has mounting features for attaching the connector 68 to the chamber.

[0095] The swash plate 52 is driven by a motor 13 (not shown in these figures) via a rotating coupling 51. The coupler 51 is fixed to the drive shaft of the motor 13 so that the coupler 51 rotates together with the drive shaft around the drive shaft. The coupler 51 has a mounting aperture 70 offset from the rotation axis of the coupler 51.

[0096] Referring to Figures 15 and 16, the swash plate 52 has a central spigot 69 that is received by an offset aperture 70 on the coupler 51. As a result, the swash plate 52 tilts because its lateral movement is constrained by its connection to the chamber 53 and the chamber housing 67.

[0097] The spigot 69 is pivotably mounted within the offset aperture 70 of the coupler 51 so that the coupler 51 can rotate relative to the swash plate 69. When the coupler 51 is driven to rotate by the drive shaft of the motor 13, the end of the spigot 69 mounted on the coupler 51 moves in a circular motion around the drive shaft, causing the swash plate 52 to tilt periodically and axially in a seesaw-like manner.

[0098] As the swash plate 52 tilts periodically, it sequentially compresses each chamber 53, and then sequentially expands each chamber 53. The compression of the chambers 53 causes the fluid present in the chambers 53 to be discharged through the respective outlet valves 55 into the outlet channels 62 and through the pump outlet 57. The subsequent expansion of the chambers 53 creates a vacuum within the chambers 53, drawing fluid into the chambers 53 from the pump inlet 56 through the inlet channels 61 and the respective inlet valves 54. This process is repeated periodically to pump the fluid from the pump inlet 56 to the pump outlet 57.

[0099] The motor 13, coupler 51, and swash plate 52 form a drive mechanism for driving the expansion and compression of the chamber 53. The swash plate 52 and coupler 51 convert the rotational motion of the motor 13 into axial motion to expand and compress the chamber 53. Other drive mechanisms are possible, such as a crank arm attached to the motor shaft and a connecting rod between the chamber and the crank arm. However, when there are two or more chambers, a motor having a coupler and swash plate is a preferred drive mechanism. In the embodiments illustrated in Figures 13 to 16, the swash plate 52 and coupler 51 are housed in a drive mechanism housing 77. The motor 13 may be mounted in the drive mechanism housing 77 (for example, as shown in the embodiment in Figure 27).

[0100] Figures 27 and 28 show an alternative pump configuration comprising three chambers 53 and three associated pairs of inlet valves 54 and outlet valves 55. The multiple pairs of flexible valves 54, 55 are provided integrally by a valve component 72. The valve component 72 comprises a flexible elastic material such as silicone and is mounted on a substantially rigid valve support 73. The valve support 73 has recesses having shapes corresponding to the valve component 72, for positioning and receiving the valve component 72. The valve support 73 further comprises multiple pairs of apertures 74, 75 corresponding to each pair of valves 54, 55. The two apertures 74, 75 of each pair are separated by a sealing bar 76. As shown in Figure 28, the valve component 72 is seated between the pump cover 58 and the valve support component 73, and is mounted on the valve support 73 with the inlet valve 54 protruding into the corresponding aperture 74 in the valve support 73. The valve component 72 may include a positioning flange molded and positioned to abut against the edge of each aperture in order to position the valves 54, 55 and to help prevent leakage through the assembly during operation.

[0101] The sealing bar 76 is positioned between the respective inlet valves 54 and outlet valves 55. The sealing bar 76 is aligned with a portion of the pump cover 58 that separates the inlet channel 61 and the outlet channel 62. When the components are assembled, the sealing bar 76 abuts against the valve components between the two valves 54 and 55, compressing the valve components at that point to form a seal and preventing fluid from bypassing the valves 54 and 55 and flowing directly between the inlet channel 61 and the outlet channel 62.

[0102] In the embodiments shown in Figures 27 and 28, the swash plate 52 has a Y-shape with three arms for connecting to each of the three compressible chambers 53. This Y-shape provides optimal clearance between the swash plate and other components in this embodiment. However, the swash plate may have an alternative shape depending on the number of connectors it drives, or it may have a substantially circular shape.

[0103] Referring to Figures 13-16 and Figures 27 and 28, the preferred pump configuration described above achieves high flow capacity with low power consumption, making the pump particularly useful for NPT systems, especially portable NPT systems.

[0104] For example, the pump described with reference to Figures 13-16, which has two chambers, has the pump characteristics described in Table 1. For comparison, the characteristics of a peristaltic pump are provided in Table 2 below. The pumps described herein have a much higher flow rate capacity for a given power consumption. For example, at 6V, the described pump has a flow rate of 220 mL / min with a power consumption of 0.33 W, compared to a peristaltic pump with a flow rate of 38 mL / min with a power consumption of 0.9 W.

[0105] [Table 1]

[0106] [Table 2]

[0107] The pump assembly 15 is particularly useful in preferred NPT systems 100, 200, 300, and 400 in which the air inlet valve 18 is opened to introduce air while maintaining negative pressure in the wound 4, as described in more detail below. Such system operation requires a high-capacity pump 15 to maintain negative pressure while introducing a considerable volume of air into the treatment system 100, 200, 300, and 400 by keeping the air inlet valve 18 open for a significant portion of the valve opening / closing cycle time. Furthermore, the pump assembly 15 is particularly useful in treatment systems comprising a treatment device 3 configured to introduce filtered air into a large portion of the total volume of the treatment site 4. Preferred treatment devices 3 are described below with reference to Figures 39 and 40. The high-capacity pump assembly 15 is required to move an increased amount of air and lift fluid from the wound 4 to the exudate reservoir 6 while maintaining negative pressure in the wound 4 at an effective treatment negative pressure level.

[0108] Prior art NPT systems, configured with a vacuum pump assembly upstream of the fluid collection reservoir and downstream of the wound treatment device, typically use peristaltic pumps because these NPT systems can handle passing tissue debris, provide the benefit of a closed system, and allow the fluid to be separated from direct contact with the moving parts of the pump. However, peristaltic pumps offer insufficient capacity in practical size and power to achieve the required treatment negative pressure and the flow rate required in a preferred system configuration.

[0109] Peristaltic pumps that provide suitable flow rates for the preferred systems described herein would not be suitable for portable systems due to their size and power requirements. The pump assembly 15 described herein allows for improved capacity (increased flow rate) with lower power compared to prior art pumps, while enabling biological materials such as blood, adipose tissue, fibrin, lysed cells, and large biological particles (2 mm in size) to pass through the pump assembly 15 without causing blockage.

[0110] The described pump assembly 15 may be useful in other applications requiring a pump with high capacity output for relatively low power input. For example, the described pump may be particularly suitable for use in portable dialysis devices or any other portable devices requiring the movement of large volumes, especially in applications requiring the movement of large volumes at pressure levels above or below ambient levels.

[0111] Sterilization filter The sterile air inlet filter 19 may comprise a PTFE membrane, for example, a PTFE syringe-type filter available from Steriltech®. In one example, the filter 19 includes a filter membrane pore size of approximately 0.2 microns. The filter membrane is approximately 1 cm². 2The filter may have an area of ​​. The filter may comprise a filter assembly including a housing for enclosing a filter film or element and having an inlet and an outlet (for example, the filter assembly 19 in Figure 25 comprises a housing 19a having an inlet 19b and an outlet 19c). A preferred filter is filter part number PT021350 provided by Steriltech®.

[0112] The filter 19 preferably provides an additional predetermined pressure drop between the ambient pressure outside the treatment systems 100, 200, 300, 400 and the pressure inside the treatment systems 100, 200, 300, 400 upstream of the treatment device 3. The pressure drop may be provided by the filter membrane and / or orifice in the flow path through the filter assembly. For example, the filter is selected to provide a pressure drop of about 20 to 130 mmHg. In an exemplary embodiment, the filter provides a pressure drop of about 100 mmHg. Alternatively, the pressure drop between the ambient environment and the upstream side of the wound treatment device may be provided by another component such as an orifice plate or other inlet throttling located upstream of the wound treatment device. When the air inlet valve is open, the inlet throttling determines the pressure in the wound, together with the control of the pump assembly downstream of the treatment device 3.

[0113] In certain embodiments, as shown in the embodiments of Figures 8 to 12, where the auxiliary conduit 12 or supply path of the vacuum pressure unit 2 includes a common connection between the air inlet valve 18 and the treatment fluid reservoir 26, the filter / filter element is preferably hydrophobic to prevent the filter 19 from becoming clogged after contact with the treatment fluid from the treatment reservoir 26. Otherwise, any type of suitable filter medium may be used.

[0114] The air filter 19 may be provided at the air inlets to the treatment systems 100, 200, 300, and 400, or within the air passages of the treatment systems. For example, the vacuum pressure unit housing may be sealed to prevent unwanted ingress of fluids (such as water from a shower or rain) into the vacuum unit 2 and to provide a passage to the air inlet valve 18 through an external opening in the housing. In this example, the sterile filter membrane may be welded to the port of the housing or otherwise attached to ensure that the air passage to the wound is sterile and biocompatible. The disadvantage of this is that all fluid contact parts of the system, including the air inlet valve 18, must be sterilized.

[0115] In a preferred embodiment, the filter 19 is located between the air inlet valve 18 and the wound site, as shown in Figures 6, 7, 9-12, and 57. This allows the non-sterile air inlet valve assembly 18 to be incorporated into the systems 100, 200, 300, and 400 within the vacuum unit housing, enabling ambient air to be drawn into the valve 18 from the surrounding environment. If an upstream pressure sensor Pv is provided, it is preferably located upstream of the filter 19, so that the sensor also does not require sterilization.

[0116] Air inlet valve and fluid inlet valve The air inlet valve 18 includes an actuator, such as a solenoid, which communicates with a controller to drive the valve between an open and a closed position. An example of a valve suitable for use as the air inlet valve 18 is the mini-solenoid valve provided by Koge™ part number KSV2WM-5A. This particular solenoid valve has a central ferromagnetic plunger component that remains nominally closed against an internal rubber seal via a force provided by an internal spring. The valve is opened by applying an electric current to generate a magnetic field that opens the plunger against the force of the spring. The valve has the advantage of automatically closing when the current is lost to maintain the vacuum pressure level in the treatment device 3, which is advantageous when power is unexpectedly lost, for example when a battery loses its charge. The disadvantage of this valve is the total amount of energy required to keep the valve open for an extended period of time.

[0117] Another example of a suitable air inlet valve 18 is the NLV-2-MFF micro-latching solenoid diaphragm isolation valve provided by Takasago Fluid Systems (Takasago Electric Industry). This solenoid valve uses a permanent magnet to maintain the valve in either an open or closed position. A current supplied to the solenoid in a first direction moves the valve from the open to the closed position, while a current supplied in a second reverse direction moves the valve from the closed to the open position. This latching solenoid valve requires electrical energy only to change the open / closed state of the valve and, therefore, unlike the KOGE(trademark) example described above, does not require energy to maintain the valve position. The lower energy demand of this valve is particularly advantageous for the treatment systems 100, 200, 300, and 400 described herein, where longer durations of valve timing may be applied by the controller. However, the power-saving advantage of this solenoid valve also presents a risk of total vacuum pressure loss to the wound treatment device 3 if power to the vacuum pressure unit 2 is lost, which can be mitigated by including a capacitor component in the electrical circuit connected to the solenoid valve.

[0118] The air inlet valve 18 does not act as a pressure relief valve; that is, the air inlet valve is not controlled to "pry open" to limit the pressure in the wound. The air inlet valve is opened and closed based on a predetermined period of time; that is, the control of the air inlet valve is time-controlled, not pressure-controlled, as will be described in more detail below.

[0119] The fluid inlet valve 22 includes an actuator, such as a solenoid, which communicates electrically with a controller to drive the valve between an open and closed position. The KOGE® solenoid and Takasago fluid systems latching solenoid valves mentioned above can be used for this purpose. Both of these valves include a movable part that is in direct contact with the treatment fluid flowing from the treatment fluid reservoir 26 to the wound treatment device 3 via the auxiliary conduit 12. For suitability for human use, the fluid contact components would need to be made from biocompatible materials and supplied aseptically.

[0120] In this case, the use of a pinch valve or a similar non-fluid contact fluid control valve, such as the ASCO® 390NO12330 two-way nominal close pinch valve, is preferable. These pinch valves have an open channel or receptacle for receiving a tube connected to a treatment fluid reservoir 26, such as an IV bag. One example is a small tube contained in the Braun Medical® Single Chamber IV Infusion Set, in which case the pinch valve would replace a roller clamp component in the IV infusion set. In the embodiments illustrated in Figures 9 and 10, a solenoid-operated pinch valve may be applied to a tube extending between the fluid port 25 and the connecting manifold 21. The solenoid-operated pinch valve has an internal spring that ensures a ferromagnetic plunger component tightens and closes the tube when the tube is inserted into the valve. The controller supplies current to the internal coil of the solenoid, where the resulting magnetic force retracts the plunger to the open position against the force provided by the spring, releasing the tube and thereby allowing the treatment fluid to flow through it. The controller continues to supply current to the solenoid when a fluid supply is required. When a supply of treatment fluid from the reservoir 26 is no longer needed, the controller stops supplying current to the solenoid, and as a result, the plunger returns to the closed position via the force applied by the internal spring.

[0121] Dressing control valve The dressing control valve 31 includes an actuator, such as a solenoid, which communicates electrically with a controller to drive the valve between an open position and a closed position. Any suitable actuator, such as the KOGE® solenoid and the Takasago fluid system latching solenoid valve mentioned above, can be used for this purpose.

[0122] Tubing Figures 31 and 32 show cross-sections of two double-lumen conduits for connecting the vacuum unit 2 and the treatment device 3. The conduit shown in Figure 31 has a circular outer wall. This conduit is preferred for wound treatment where the conduit must be removed afterward without opening the wound, for example, without internal wound treatment. The round or circular outer wall allows the conduit to be rotated during removal to gently release any tissue adhering to the sides of the conduit that may cause discomfort to the patient.

[0123] To provide a circular outer wall, the main lumen 11 and the secondary lumen 12 are provided side by side. The secondary lumen or supply lumen 12 has a circular cross-section, and the main lumen or removal lumen 11 has a crescent cross-section to partially enclose the secondary lumen 12 or to surround the secondary lumen 12. The main lumen 11 has a larger cross-sectional area than the secondary lumen 12.

[0124] The conduit cross-section in Figure 32 is preferred for use with or as part of a wound treatment device for treating trauma, as described below with reference to Figures 39 to 42. The conduit comprises a main lumen or removal lumen 11 and a secondary lumen or supply lumen 12, adjacent to an inner wall W separating the two lumens, and the two lumens have a circular cross-section.

[0125] For example, the supply lumen is approximately 1.7 mm. 2 It may have a cross-sectional area of ​​approximately 9 mm, and the removed lumen is approximately 9 mm. 2 It may have a cross-sectional area of ​​. The typical length of the tubing between the vacuum unit and the treatment device is about 1000 mm. In other embodiments, the cross-sectional area of ​​the supply lumen is about 0.7 mm². 2 ~3mm 2 It can be within the range, and the main lumen is approximately 2 mm. 2 ~approximately 30mm 2 The length of the supplied tubing varies, ranging from approximately 200mm to about 1500mm.

[0126] Wound treatment devices An exemplary treatment device 3 for use in internal wounds is shown in Figure 7, which is similar to the treatment device schematically shown in Figure 6, which has a single tubular channel at the wound treatment site. Treatment device 3 provides a fluid channel through the wound treatment site 4. Treatment device 3 includes a perforated conduit 3a having an upstream end 3b and a downstream end 3c. A fluid, such as air, is supplied to the treatment device and the wound site via the upstream end 3b of treatment device 3. Fluids, such as air and exudate, are removed from the wound and treatment device 3 via the downstream end 3c of treatment device 3. In the exemplary embodiment, treatment device 3 provides a single channel through the treatment device, i.e., the treatment device conduit does not have branches. In such an arrangement, if the portions of the treatment device conduit are close to each other, a “short-circuit” path SC may exist, thereby causing flow to preferentially occur between the two portions of the treatment device conduit 3a that are close to each other. This prevents the fluid flow from reaching other areas of the treatment site and prevents flow to and from those areas.

[0127] In some embodiments, the treatment system may include a trauma treatment device for delivering treatment fluid and / or air and providing subsequent removal of fluid from the wound while maintaining a near-atmospheric (negative) pressure environment.

[0128] Figure 39 shows a treatment system comprising a trauma treatment device 40. As described above for embodiments 200 and 300 in Figures 8 to 12, the vacuum unit 2 is connected to the treatment fluid source 26 and the wound exudate reservoir 6 via a conduit, and to the treatment device 40 via a double-lubricated conduit 5. However, the wound treatment system does not have to include a treatment fluid supply unit, as described for embodiment 100 in Figures 6 and 7.

[0129] Figure 40 is an exemplary cross-sectional view of the trauma treatment device 40 shown in Figure 39, where the cross-sectional view corresponds to the line represented by "x" in Figure 39.

[0130] The trauma treatment device 40 comprises a porting component or layer 41 (wound filler), a covering dressing or layer 42, a supply conduit 12, and a (separate) removal conduit 11. The porting component 41 is positioned within the wound cavity to fill the wound treatment space. The covering dressing is adhered to an area of ​​undamaged, intact skin surrounding the wound (also known as the peri-wound area). The dressing covering 42 is made from a material that allows adhesion to the peri-wound area while providing an airtight seal, such as a polyurethane film containing a layer of pressure-sensitive acrylic adhesive, to allow for the maintenance of vacuum pressure within the wound site. Such materials are known in the art.

[0131] The treatment device 40 comprises two separate conduits 11 and 12 within the treatment space of the wound. The conduits 11 and 12 may be the terminal portions of a supply conduit 12 and a removal conduit 11 that extend between the treatment device 40 and the vacuum unit 2. In the case of a double-lumen conduit, the terminal portion of the double-lumen conduit may be divided into two separate rims: a removal or exudate rim (removal conduit) and a supply rim (supply conduit).

[0132] As discussed above, the supply conduit 12 provides the supply of air containing treatment agents and therapeutic agents, or air and fluid, to the wound, as well as the supply of sterile air. The removal conduit 11 provides the removal of exudate from the wound.

[0133] In Figure 39, both conduits 11 and 12 have perforations or apertures 11a and 12a of equal or different sizes to allow fluid exchange to the target treatment site. The ends of the conduits may be blocked / blocked so that flow from and to each conduit passes through perforations along the length of these conduits. Alternatively, the ends also present outlets and inlets for the supply and removal conduits, respectively. The perforations are spaced apart along the conduits and may be placed at repeated or varying distances along the conduits to reduce potential pressure loss that may occur along the length of the conduits. The perforations or apertures 11a and 12a provide one or more outlets from the supply conduit 12 and one or more inlets to the exudate conduit 11.

[0134] The porting component or porting layer 41 may be formed from any suitable biocompatible material that can facilitate fluid flow through or around the porting layer 41, and includes, but is not limited to, polyurethane foam, polyvinyl alcohol foam, nonwoven fabric, spacer fabric, gauze, mesh foam, plastic mesh material, or elastomer components constructed from silicone, thermoplastic elastomer, or polyurethane, which provide sufficient structural integrity to prevent the collapse of the covering dressing material into the wound under applied vacuum pressure.

[0135] Wound contact components may also be additionally placed between the wound and the porting components to promote wound healing and may include extracellular matrix (ECM) grafting materials such as decellularized human or animal tissues isolated from various organs, as well as from diverse animal connective tissue and basement membrane sources. Other possible wound contact components include natural polymer materials such as proteins, polysaccharides, glycoproteins, proteoglycans, or glycosaminoglycans. Examples include collagen, alginate, chitosan, and silk. Alternatively or additionally, wound contact components may include synthetic polymer materials such as polypropylene, polytetrafluoroethylene, polysiloxane (silicone), polyglycolic acid, polylactic acid, polyglecapron-25, or polyester. Wound contact components may include combinations of one or more layers of the above materials.

[0136] The wound treatment space shown in Figure 40 is defined by the covering dressing 42 and the wound treatment surface of the trauma (open wound). The treatment device 40 is applied to the wound treatment space to facilitate the supply of fluid to and removal of fluid from the treatment space. The treatment space includes a fluid supply conduit 12, an exudate removal conduit 11, and a porting component or layer 41.

[0137] The fluid flow from the supply conduit 12 through the porting component 41 to the exudate removal conduit 11 is indicated by the arrow in Figure 40. The porting component 41 ensures that the supplied treatment fluid and / or air is distributed to the treatment surface within the wound while maintaining a negative pressure level within the wound treatment space.

[0138] As shown in Figures 39 and 40, the fluid supply conduit 12 and the exudate or removal conduit 12 are arranged to avoid or prevent “short-circuit” passages between the two conduits and through the wound treatment space. This arrangement improves fluid flow through a substantial portion of the treatment space, preferably substantially the entire treatment space. Short-circuits can result in preferential fluid flow to only a portion of the treatment space rather than supplying fluid to substantially the entire treatment space.

[0139] To avoid short-circuits through the wound treatment space, in a preferred embodiment, the two conduits 11 and 12 are positioned opposite each other in the porting layer, i.e., in or adjacent to the periphery of the porting layer and / or the wound treatment site. In Figures 39 and 40, the two conduits are positioned opposite each other in or adjacent to the periphery of the porting layer or the wound treatment space. The supply conduit 12 and the removal conduit 11 are preferably positioned at the maximum distance apart within the wound treatment space.

[0140] In the illustrated embodiment, the supply conduit and removal conduit are located on one side of the porting layer. However, in other embodiments, the conduits may be located on opposing sides of the porting layer or embedded in the porting layer. When located on the side of the porting layer (e.g., the outermost surface, the surface furthest from the wound), the supply conduit and removal conduit are preferably provided in the porting layer such that the inlet aperture 11a and outlet aperture 12a face the surface of the porting layer 41 or are positioned in abutment with the surface.

[0141] In Figure 39, the supply conduit 12 and the removal conduit 11 are arranged such that there is a certain distance between the outlet 12a and the inlet 11a of each conduit. The minimum distance between the inlet 11a and the outlet 12a is several times greater than the maximum distance between adjacent outlets 12a along the length of the supply conduit 12. The minimum distance between the inlet 11a and the outlet 12a is several times greater than the maximum distance between adjacent inlets 11a along the length of the exudate conduit 11. For example, the minimum distance between the inlet and the outlet may be 5, 6, 7, 8, 9, or 10 times greater than the maximum distance between adjacent inlets and / or adjacent outlets.

[0142] In some embodiments, a perforation / aperture 12a may be provided only to the supply conduit 12, without a perforation or aperture along the removal conduit 11. Referring to Figures 41 and 42, the supply conduit 12 has an outlet 12a along its length, as described above, while the removal conduit 11 has no inlet along its length. The fluid flow from the supply conduit 12 to the removal conduit 11, as shown by the dashed lines in Figures 41 and 42, is from the outlet 12a, which is spaced apart along the supply conduit 12 and the open end of the supply conduit 11, through the porting layer 41 to the end of the removal conduit 11. The open end of the removal conduit 11 provides an inlet aperture 11a.

[0143] Alternatively, the perforation / aperture 11a may be provided only in the removal conduit 11 without a perforation or aperture along the supply conduit 12, in which case the open end of the removal conduit 12 provides an inlet aperture 12a.

[0144] In a preferred embodiment, the treatment device 40 comprises a double-lubricated conduit 5 having a supply lumen and an outlet lumen. The end portion of the conduit 5 is divided along the length of the end portion, separating the conduit into a supply conduit portion 12 having a supply lumen and an outlet conduit portion 11 having an outlet lumen. For example, the conduit shown in Figure 32 is divided along the length of the conduit through an inner wall W separating the two lumens and is not divided into either lumen. Notches may be provided along the length of the conduit to form an aperture in the side wall of the supply or outlet conduit. For example, as shown in Figure 41, spaced-out notches are made through the conduit wall to enter the lumen and form an aperture that penetrates the wall of the conduit. In the illustrated embodiment, the notches or notches are made through the inner wall W of the conduit. In Figure 42, a spiral notch is made along the length of the conduit 12 to provide a flow path along the length of the conduit. In some embodiments, the inner wall W of the double-lumen conduit is separated between the two rims, so that the inner wall may have a portion that is thinner than the outer wall portion of the conduit, and as a result, the helical notch completely penetrates the inner wall portion of the conduit without completely penetrating the outer wall portion of the conduit, presenting an aperture 12a spaced along the length of the conduit. Embodiments in Figures 41 and 42 provide a convenient and cost-effective method for providing a supply conduit and an removal conduit to a wound treatment device, avoiding the need for connectors. Each notch or notch preferably provides a small aperture through the wall of the conduit, for example, for a supply conduit, an aperture having a diameter of about 0.6 mm or less.

[0145] As shown in Figures 41 and 42, the treatment device may include a bridging component 43 through which a double-lumen conduit 5 passes, as described in U.S. Provisional Patent Application No. 62 / 568,914 (the contents of which are incorporated herein by reference). The bridging component 43 is fixed to the patient's skin and facilitates sealing between the upper cover 42 of the treatment device and the patient's skin.

[0146] manifold As described with reference to Figures 3, 6, 7, 9, and 10, in some embodiments, the vacuum unit 2 includes connection or interface manifolds 20, 21 for connecting wound treatment devices 3, 30, 40 to the vacuum pressure unit 2, and in embodiments of Figures 9 to 12 and 39, it includes connection or interface manifolds 20, 21 for connecting a treatment fluid reservoir 26 to the fluid supply path of the vacuum unit 2.

[0147] Figures 24 to 26 illustrate an interface manifold 20 for use in the embodiments of Figures 6 and 7. The manifold 20 comprises a first fluid passage 201 having a first inlet 202 and a first outlet 203, and a second fluid passage 204 having a second fluid inlet 205 and a second fluid outlet 206. The first inlet 202 is connected to an air inlet valve 18, and the first outlet 203 is connected to a supply conduit 12 from the vacuum unit 2 to the treatment device 3. The second inlet 205 is connected to a removal conduit 11 from the treatment device 3 to the vacuum unit 2, and the second outlet 206 is connected to a pump inlet 56. The first outlet 203 and the second inlet 205 provide a fluid outlet to the treatment device 3 and a fluid inlet from the treatment device 3. In the illustrated embodiments, the manifold is equipped with a sterilization filter 19 in the first fluid passage 201. In this embodiment, the sterile filter is provided as a separate assembly comprising a housing 19a and an internal filter element, the filter housing 19a being housed in a first flow path 201 of a manifold 20 (not shown in Figure 26). Thus, the connecting manifold 20 provides a convenient connection interface between the system's input and output to the treatment device 3, while also ensuring a sterile interface for an air inlet to the treatment system 100. The illustrated embodiment also includes a one-way valve 207 in a second flow path 204 to prevent backflow in the removal conduit from the pump to the treatment device.

[0148] Figures 20 to 23 illustrate an interface manifold 21 for use in the embodiments shown in Figures 9 to 12. The manifold 21 comprises a first fluid passage 201 having an air inlet 202 and a treatment fluid inlet 208, which are in fluid communication with a first outlet 203, and a second fluid passage 204 having a second fluid inlet 205 and a second fluid outlet 206. The air inlet 202 is connected to an air inlet valve 18, and the treatment fluid inlet 208 is connected to a treatment fluid reservoir 26. The first outlet 203 is connected to a supply conduit 12 from the vacuum unit 2 to the treatment device 3. The second inlet 205 is connected to a removal conduit 11 from the treatment device 3 to the vacuum unit 2, and the second outlet 206 is connected to a pump inlet 56. The first outlet 203 and the second inlet 205 provide a fluid outlet to the treatment device 3 and a fluid inlet from the treatment device 3.

[0149] In the illustrated embodiment, the manifold 21 includes a sterilization filter 19 in the first fluid passage. The sterilization filter 19 comprises a filter membrane received in the first fluid passage 201. Thus, the connecting manifold 21 provides a convenient connection interface between the input and output of the system to the treatment device 3, while simultaneously ensuring a sterile interface for air inlets to the systems 200, 300. In a preferred embodiment, the manifold includes a one-way valve 207 in the second passage 204 to prevent backflow in the removal conduit from the pump to the treatment device. The connecting manifold 21 may also include an additional one-way valve 33 in the first passage, positioned adjacent to the sterilization filter 19, to prevent fluid ingress from the treatment fluid from damaging the sterilization filter 19.

[0150] Figure 19 illustrates a manifold 21a that is very similar to the manifold 21 in Figures 20-23. Manifold 21a has the same internal features as manifold 21 described above. Manifold 21a is connected to connection port 25 via a tube 27 for connecting to a treatment fluid reservoir 26 outside the vacuum unit 2. The manifold 21a (or 21), tube 27, and connection port 25 are preferably provided as a single sterile connection assembly for the pump unit 2. Thus, the connection assembly provides a convenient connection interface between the system's inputs and outputs to the treatment device 3, while simultaneously ensuring sterile interfaces for air inlets and treatment fluid inlets to the systems 200, 300.

[0151] A tube clamp 28 may be provided on the tube 27 to provide a means for clamping and closing the tube 27 when the treatment fluid is no longer needed. In an alternative embodiment, the tube clamp 28 may be partially closed to provide a means for controlling the flow of treatment fluid into the system, or it may replace a roller clamp to provide a means for controlling the flow of treatment fluid into the system. Additionally or alternatively, an orifice may be included, for example, in the tube 27 or in the manifold 21a, allowing a Pv sensor to measure the resulting pressure drop across the orifice when the treatment fluid is flowing. The pressure measured by the Pv pressure sensor allows the flow rate of treatment fluid from the reservoir 26 to be calculated via the application of Bernoulli's equation. In an alternative embodiment, the tube clamp 28 may be replaced by an electrically operated valve that communicates electrically with a controller, for example, the valve 22 described above with reference to Figures 9 and 10. For example, the valve 22 may be a solenoid-operated valve, for example, a solenoid-operated pinch valve that operates a plunger biased to a closed position by a spring. The controller 17 operates a solenoid to retract the plunger against the spring bias, thereby opening the valve. The valve can then close by tightening the tubular line 27, creating a vacuum airtight seal. In some embodiments, as illustrated in Figures 11 and 12, the system may not have a treatment fluid valve controlled by the controller.

[0152] Figures 17 and 18 show the manifold 21a of Figure 19 connected to the pump assembly 15, where the pump inlet 56 is directly connected to the second outlet 206 of the second flow path 204 of the manifold, and the air inlet 202 of the manifold is directly connected to the through spigot 66 of the pump assembly 15 to connect to the air inlet valve 18.

[0153] The manifold one-way valve 207 is preferably an elastic / flexible valve, such as a duckbill valve, as described above with respect to the one-way valve incorporated into the pump assembly 15.

[0154] The connecting manifolds 20, 21, and 21a preferably comprise molded parts welded together or otherwise assembled to form a fluid-tight and airtight assembly. The manifolds 20, 21, and 21a are receptacled by connectors, such as mating tubing / conduits or valves / pumps, or spigots or receptacles for receiving them, for fluid connections to other parts of the system. The valves are preferably molded from liquid silicone rubber.

[0155] Overall assembly Figures 33 to 36 show the overall assembly drawings of the vacuum unit 7 according to the embodiments shown in Figures 6 and 7.

[0156] As previously mentioned, the vacuum unit 2 comprises a housing for housing various components of the unit, including a pump assembly 15 with a motor 13, a user interface 14, a battery 16, a controller 17, an air inlet valve 18 with an actuator, pressure sensors Pv, Pp, and a sterilization filter 19. In this embodiment, the vacuum unit 2 comprises the connection manifold 20 described above with reference to Figures 24-26. A connector 10 for communicating with the collection reservoir 6 is also shown in the figures, but the connecting hoses or tubing / conduits between the manifold 20 and the air inlet valve 18, and between the connector 10 and the pump outlet 57, as well as the conduits from the manifold 20 to the treatment device 3, are omitted for clarity. Electrical wiring is also omitted for clarity.

[0157] Figures 37 and 38 show overall assembly drawings of the vacuum unit 2 of the embodiments of Figures 11 and 12, which additionally include tube clamps 28 on the tubes 27 connecting the manifolds 21 / 21a to the treatment fluid reservoir 26, as described above with reference to Figure 19. The illustrated embodiments are similar to the embodiments of Figures 33–36, except that alternative interface manifolds 21, 21a are provided with the tubes 27, tube clamps 28 and associated connection ports 25 for connecting the treatment fluid reservoir 26, and the housing incorporates an aperture for receiving the connection ports 25.

[0158] As can be seen from the two embodiments in Figures 33 to 38, the vacuum unit can be easily configured between the two embodiments by selecting appropriate interface manifolds 20, 21 and a housing having or not having an aperture for the treatment fluid reservoir connection port 25. The controller of each embodiment of the vacuum unit may include a switch for configuring the controller for an "air only" embodiment or an embodiment that also has a treatment fluid supply option.

[0159] System operation Here, the operation of the treatment system 100 described above will be described with reference to Figures 6 and 7, and then with reference to Figures 44 to 50. First, referring to Figures 44 and 45, the system includes a user interface 14 to enable the user to operate the system. The user interface may provide the user with visual (e.g., LED) and audio instructions for system settings, and inputs, such as one or more buttons 23 (Figure 56), may enable, for example, turning a unit on / off, operating a pump, or selecting an operating mode. The controller 17 electrically communicates with the air valve actuator (18a in Figures 35 and 36), the pump motor 13, and pressure sensors Pv, Pp to provide system logic and control algorithms for controlling the air inlet valve 18 and the pump assembly 15. The controller may also communicate with the power management and sensor circuits to manage the power supply 16 and, for example, provide the user with battery charging instructions via the user interface.

[0160] The controller is configured to operate the pump assembly 15 to maintain negative pressure in the wound 4 via the wound treatment device 3 while opening and closing the air inlet valve. The air inlet valve 18 is opened to introduce air into the wound site, while the pump assembly continues to operate to maintain negative pressure in the wound.

[0161] Negative pressure treatment can lead to a stagnant system, even when the wound continues to produce exudate. In a stagnant system, the system is effectively sealed from the surrounding environment, and no fluid transfer or flow from the wound to the exudate reservoir 6 is achieved. This can exacerbate system occlusion due to coagulation of blood, fibrin, etc., in the wound and / or elsewhere in the system. Occlusion ultimately leads to a failure to provide negative pressure in the wound, rendering negative pressure treatment ineffective.

[0162] To avoid a stagnant system, the controller keeps the pump assembly 15 running to maintain negative pressure in the wound while opening and closing the air inlet valve 18.

[0163] For example, the treatment system 100 is configured to open the air inlet valve 18 to introduce air to the wound site while maintaining a vacuum pressure (first vacuum pressure) of at least 40 mmHg, preferably at least 50 mmHg, at the wound site 4 / wound treatment device 3. In an exemplary embodiment, the treatment system can open the air inlet valve to introduce air to the wound and maintain a vacuum pressure of approximately 50 mmHg to 100 mmHg, or approximately 60 mmHg to 100 mmHg, or 70 mmHg to 100 mmHg, or 80 mmHg to 100 mmHg at the wound site / wound treatment device. When the controller closes the air inlet valve, the pump continues to operate to maintain negative pressure at the wound. When the air valve is closed, the vacuum pressure at the wound site 4 may be approximately 100 mmHg to 150 mmHg (second vacuum pressure).

[0164] Preferably, the vacuum pressure maintained in the wound treatment device when the air inlet valve is open is at least a substantial portion of the vacuum pressure maintained in the wound when the air inlet valve is closed, or may be equal to the vacuum pressure maintained in the wound when the air inlet valve is closed. For example, the vacuum pressure maintained in the wound with the air valve open may be approximately 30% to 100% of the vacuum pressure maintained in the wound with the air valve closed, or approximately 50% to 100%, 70% to 100%, or about 80% of the vacuum pressure maintained in the wound with the air valve closed.

[0165] When the air inlet valve is closed, the vacuum pressure in the wound may be approximately 20-50 mmHg higher than the vacuum pressure in the wound when the air inlet valve is open, or it may be equal to the vacuum pressure in the wound when the air inlet valve is open.

[0166] In a preferred embodiment, the system is configured to circulate the air inlet valve between an open and closed position while maintaining negative pressure in the wound. When the air inlet valve is closed, the system quickly returns to a stagnant state. To avoid remaining in a stagnant state which could lead to blockage formation, the controller is configured to reopen the air inlet valve while maintaining negative pressure in the wound, and then reopen the air inlet valve. The opening and closing of the air valve continues. Introducing air into the system while maintaining negative pressure in the wound facilitates the movement of fluid from the wound to the reservoir and reduces the risk of blockage. In some embodiments, the treatment system may be configured to keep the air inlet valve open and closed to achieve continuous pump operation, maintain fluid flow, and avoid remaining in a no-flow or stagnant state for extended periods.

[0167] In a preferred embodiment, the system is configured such that when the air inlet valve 18 is opened, the flow rate of air into the treatment system through the air inlet valve 18 equals the flow rate of fluid (e.g., exudate) and air through the pump, and the system achieves equilibrium. In equilibrium, the vacuum pressure in the wound treatment device 3 is maintained at a steady state or a constant vacuum pressure level (first vacuum pressure), or reaches this vacuum pressure level. The system may achieve a constant vacuum pressure level after a short duration, e.g., a few seconds or less, e.g., five seconds or less. In some embodiments, when the air valve is open and in equilibrium, the pressure drop across the entire treatment device is substantially zero, and substantially all of the pressure drop between the system vacuum pressure and the ambient pressure occurs across the entire inlet throttling, provided, for example, by the air inlet filter. In some embodiments, when the air inlet valve is open and in equilibrium, the pressure drop across the entire treatment device is constant. Introducing air into the wound can create a pressure drop across the entire wound site between the upstream and downstream sides of the treatment device, enabling fluid transfer from the wound 4 to the reservoir 6, thereby reducing the risk of coagulation and system blockage.

[0168] When the air valve is closed, the pump is controlled to maintain negative pressure in the wound, and the flow rate from the wound to the pump is proportional to the patient's wound response, i.e., the flow rate is proportional to the exudate produced in the wound. When the air inlet valve is closed, the pump is controlled to maintain the vacuum pressure in the wound treatment device at a steady state or a constant vacuum pressure level (second vacuum pressure). Again, the system can achieve a constant vacuum pressure level after a very short duration, e.g., a few seconds or less, e.g., 5 seconds or less. As mentioned above, the first vacuum pressure is less than or equal to the second vacuum pressure.

[0169] The steady-state vacuum pressure in the wound treatment device 3 with the air inlet valve 18 open may be less than the steady-state vacuum pressure in the wound treatment device with the air inlet valve closed. However, the vacuum pressure in the wound treatment device 3 with the air inlet valve open is sufficient for effective negative pressure treatment. As described above, the first vacuum pressure is at least a substantial part of the second vacuum pressure and may be equal to the second vacuum pressure. Therefore, periodically opening and closing the air inlet valve while operating the pump to continuously achieve treatment negative pressure not only improves exudate removal and reduces the risk of system occlusion, but also maintains a negative pressure environment in the wound for effective wound treatment.

[0170] Circulating the opening and closing of an air inlet valve while maintaining negative pressure in the wound achieves reduced fluid density at the wound site through the introduction of air. Often, for example, when the patient is upright or standing, there is a difference in height at the wound site. This difference in height in the wound can result in fluid remaining stationary at the bottom of the wound, with flow only in the upper part of the wound. By introducing air throughout the wound site, the air reaching the bottom of the wound can lift the fluid from those bottom parts, improving fluid movement throughout the wound. The introduction of air essentially allows the system to operate almost like an air pump, allowing the lower-density fluid to move "up" or against gravity. Preferred embodiments of treatment devices for providing fluid flow to avoid areas in some parts of the wound where the flow is reduced or zero are described above with reference to Figures 39–42.

[0171] The inventors have additionally identified a preferred operating mode in which the air valve is operated between an open and closed position while maintaining negative pressure in the wound, in order to introduce air into the system at a flow rate that achieves a “bubble flow” or “slug flow” from the wound site to the reservoir. Figure 43 illustrates the range of flow types in the fluid, including both liquid and gaseous states. Introducing a large amount of air by leaving the air inlet valve open for an excessively long time can result in an annular type of flow in which the exudate flows along the inner wall of the conduit and the air flows through the center of the conduit. This can cause the exudate to stagnate on the wall of the conduit, which can lead to the solidification of the fluid. The solidified layer of fluid can increase over time and lead to blockage. By circulating the opening and closing of the air inlet valve, the liquid exudate can reform a uniform column in the flow path of the system when the air valve is closed, and the subsequent opening of the air inlet valve to introduce air results in bubbles or slug of air passing through the exudate. The air valve is closed again before annular flow is achieved. The inventors believe this results in improved exudate removal and reduced blockage.

[0172] Here, with reference to Figures 46 to 50, an exemplary implementation of circulating the air inlet valve between open and closed during NPT is described. As illustrated in Figure 46, the controller is configured to implement an airflow mode or state in which the air inlet valve is open and the pump operates to achieve negative pressure in the wound, and a non-airflow mode or state in which the air inlet valve is closed and the pump operates to achieve negative pressure in the wound. In the exemplary embodiment, the non-airflow states include a pressurized state, a hold state, and a timeout state.

[0173] Referring to Figure 47, in an airflow state, the controller opens the air inlet valve to allow air to enter the system upstream of the treatment device and activates the pump to achieve the pressure threshold. For example, if the pressure sensed by the pressure sensor Pp downstream of the treatment device is below the pressure threshold, the controller activates the pump (turns on the pump). In other words, if the pressure at Pp is equal to or greater than the threshold pressure, the controller turns off the pump.

[0174] In the illustrated embodiment, the downstream pressure threshold (Pp) of the treatment device is a portion of the upstream pressure threshold (Pv) of the treatment device when the air inlet valve is closed. In the illustrated embodiment, the downstream pressure threshold (Pp) of the treatment device is 80% of the upstream pressure threshold (Pv) of the treatment device when the air inlet valve is closed. For example, when the air inlet valve is closed, the upstream pressure threshold at Pv of the treatment device is 100 mmHg, and in an airflow state with the air inlet valve open, the pressure threshold at Pp is 80 mmHg.

[0175] The pump can be repeatedly switched on and off, for example under PID control by a controller, to maintain vacuum pressure downstream of the wound treatment device with the air inlet valve open. Preferably, the system is configured to achieve a threshold pressure downstream of the treatment device at Pp in a very short time, i.e., within a few seconds, for example, less than 5 seconds. The air inlet valve remains in the open position for a period of time. When the air inlet valve is open, the pressure at the wound is maintained constant. In the illustrated embodiment, the air inlet valve remains in the open position for 14 seconds. After 14 seconds, the controller closes the air inlet valve, and the controller transitions to a pressurized state without airflow.

[0176] The parameters of the airflow state described above are provided as examples. In some embodiments, the system may not have a pressure sensor Pp downstream of the treatment device. The pump may have a suitable capacity so that it operates at a predetermined speed corresponding to a particular system performance to achieve a known or acceptable pressure level (first vacuum pressure) in the wound treatment device with the air inlet valve open. Additionally or alternatively, the system may include a pressure relief valve for introducing air into the system at the pump inlet to ensure that the vacuum pressure generated by the pump does not increase excessively high. However, in a preferred embodiment, the system includes a pressure sensor Pp, and the controller operates the pump so that the pressure does not increase above a predetermined pressure threshold, which in the above example is 80 mmHg. Other pressure thresholds are possible depending on the desired treatment plan. Preferably, the controller implements PID control to achieve precise control of the pump, and therefore control of the vacuum pressure in the wound. The controller may use pulse-width modulation (PWM) or pulse-period modulation in controlling the pump motor.

[0177] As shown in Figures 6, 7, and 9-12 and 57, in exemplary embodiments, the pressure sensor Pv is located on the periphery side of the filter. The sterilization filter 19 presents a known pressure drop to prevent the vacuum pressure in the treatment device from collapsing to ambient pressure when the air inlet valve is open. When the pressure sensor Pv is located on the periphery side of the filter, the sensor Pv essentially measures the ambient pressure when the air inlet valve is open. Therefore, when the air inlet valve is open, the pressure sensed by the sensor Pv is not used to control the pump, and the pump operates until the pressure sensed by Pp increases above a pressure threshold. In some embodiments, the pressure at Pp does not reach the pressure threshold when the valve is open. The pump may operate continuously when the air inlet valve is open, but this is less desirable.

[0178] Referring to Figure 48, in the pressurized state, the air inlet valve is closed, and the controller operates the pump to reach a pressure threshold and achieve a known or acceptable vacuum pressure (second vacuum pressure) in the wound treatment device. When the air valve is closed, the vacuum pressure in the wound treatment device may increase compared to the vacuum pressure achieved in airflow mode. In the illustrated embodiment, if the pressure sensed by the upstream pressure sensor Pv of the treatment device is less than 100 mmHg and the pressure sensed by the downstream pressure sensor Pp of the treatment device is less than 150 mmHg, the controller operates the pump. In other words, if the pressure Pv is 100 mmHg or greater, or the pressure Pp is 150 mmHg or greater, the controller turns off the pump.

[0179] The system may be configured to achieve a threshold pressure within a very short duration of closing or opening the air inlet valve, i.e., within a few seconds, for example, less than 5 seconds. When the air valve is closed, the system is closed or sealed, so the system very quickly reaches a state of stagnant flow or no flow, with zero pressure drop throughout the treatment device, thus pressure at Pv = pressure at Pp. In the illustrated embodiment, since the pressure threshold at Pv is less than the pressure threshold at Pp, the controller controls the pump based on the upstream pressure sensor Pv, which is the lower of the two pressure thresholds. However, a pressure drop through the system may occur if tissue debris and / or coagulating materials such as fibrin accumulate in the wound treatment device and / or pump, in which case a pressure difference measured by sensors Pv and Pp may occur between the upstream and downstream sides of the treatment device. Before reaching the lower threshold upstream of the treatment device, the system constraint may cause the system pressure to reach the upper threshold downstream of the treatment device, in which case the pump is controlled to the upper pressure threshold at Pp based on the downstream pressure sensor Pp.

[0180] When the pressure threshold is reached, the controller turns off the pump and transitions to a hold state. The pressurized state includes a timeout check so that if the pump does not reach the pressure threshold (e.g., at Pp) within 120 seconds, the motor is turned off and the controller transitions to a timeout state. This may be caused by other failure modes, such as blockage or leakage in the system.

[0181] Referring to Figure 49, in the holding state, the controller maintains the air inlet valve in the closed position and keeps the pump running, maintaining the desired or acceptable vacuum pressure in the wound treatment device by turning the pump on and off under PID control to achieve a desired pressure threshold, for example, Pv or Pp. The controller maintains the vacuum pressure by closing the air inlet valve for a period of time. In the illustrated embodiment, the air inlet valve is closed for 20 seconds. After 20 seconds, the controller returns to airflow mode and the cycle of opening and closing the air inlet valve is repeated. The opening and closing of the air inlet valve can be cyclical to achieve the benefits described above.

[0182] The exemplary implementation described above provides an air inlet valve open time of 14 seconds and an air inlet valve closed time of 20 seconds. These periods are examples, and alternative periods may be implemented. However, it should be noted that the air inlet valve is open for a substantial portion of the entire opening and closing cycle. In this embodiment, the entire opening and closing cycle or “cycle pitch” is 34 seconds, and the air inlet valve is open for 14 seconds of the 34-second period, or for about 40% of the entire cycle. In some embodiments, the air inlet valve is open for at least 10% of the cycle pitch, or at least 20% of the cycle pitch, or at least 30% of the cycle pitch, or at least 40% of the cycle pitch. For example, the air inlet valve open period may be approximately the same as the closed period (50% of the cycle pitch). In some embodiments, the air inlet valve may be open for more than 50% of the entire cycle.

[0183] The exemplary system configuration described above provides a cycle time of 34 seconds. However, longer or shorter cycle times are possible. As mentioned above, the ideal is to open and close the air inlet valve as needed to achieve a slug or bubble flow from the wound site to the reservoir while maintaining negative pressure at the wound. The maximum valve cycle time may be one minute or several minutes. However, the air inlet valve should be open for at least approximately 10 seconds at the above pressure to ensure that sufficient air is introduced into the system. The air inlet valve may be open for 10 to 40 seconds in each air inlet valve open / close cycle.

[0184] The duration for which the air inlet valve is open or closed depends on the air inlet flow restriction, pump capacity, treatment device configuration, and the length and diameter of the supply and exudate conduits. The system components and control parameters described above are provided as examples. However, the inventors believe that the system parameters should be selected to allow the air inlet valve to be open for a considerable duration while maintaining the negative pressure in the wound at a level useful for negative pressure treatment of the wound.

[0185] Referring to Figure 50, an exemplary embodiment includes a timeout state to safely manage situations where the system cannot reach the intended negative pressure level. As described above with reference to Figure 48, if the system cannot pressurize when the air inlet valve is closed after a predetermined period (e.g., 2 minutes), the controller transitions to a timeout state. The controller pauses pump operation for 30 seconds and increments the timeout counter. If the timeout counter is below a predetermined count threshold, the controller then returns to the pressurizing state and attempts to pressurize the wound treatment site. If the timeout counter threshold is reached, the controller returns to the airflow state. As described above, introducing air can reduce blockages. The system may fail to pressurize due to blockages. Returning to the airflow state can remove blockages before returning to the pressurizing state.

[0186] In some embodiments, the treatment system may implement other control parameters not shown in Figures 46-50. For example, in some embodiments, the system includes a pressure sensor Pv upstream of the treatment device and a pressure sensor Pp downstream of the treatment device. The controller may operate the pump and / or air inlet valve based on the pressure difference measured between the two pressure sensors. For example, the controller may open the air inlet valve when the pressure difference increases above an upper threshold or exceeds the upper threshold for a predetermined period of time. The system pressure difference may indicate blockage in the system, particularly when the air inlet valve is closed. When the air valve is closed and the system is stagnant, the pressures upstream and downstream of the treatment device should be substantially equal. The controller may close the air valve when the pressure difference decreases below a lower threshold or remains below the lower threshold for a predetermined period of time. The controller may stop the pump and / or airflow state when the pressure difference increases above an upper or maximum threshold.

[0187] As described above with reference to Figures 8 to 12, in some embodiments the system is configured to introduce a treatment fluid into the wound. In the systems of Figures 9 and 10, the controller may be configured to operate a treatment fluid inlet control valve 22 to introduce the treatment fluid in a manner similar to the operation of the air inlet valve 18. The treatment fluid reservoir 26 is preferably at ambient pressure.

[0188] The controller operates the pump to maintain negative pressure in the wound treatment device while opening the fluid inlet valve 22 to draw treatment fluid into the treatment device. In a preferred embodiment, when the fluid inlet valve 22 is opened, the system is configured to achieve equilibrium at a flow rate of treatment fluid from the treatment fluid reservoir 26 into the treatment system equal to the flow rate of fluid (e.g., exudate and treatment fluid) passing through the pump. In equilibrium, the vacuum pressure in the wound treatment device is maintained at a steady state or a constant vacuum pressure level (i.e., a third vacuum pressure), or reaches this vacuum pressure level. The system may achieve a constant vacuum pressure level after a very short duration, e.g., a few seconds or less, e.g., 5 seconds or less. In a preferred embodiment, when the fluid inlet valve is open and equilibrium is reached, the pressure throughout the treatment device is substantially zero.

[0189] When the fluid inlet valve is open, the controller can operate the pump to achieve the same pressure in the treatment device that the treatment system achieves when the air inlet valve is open.

[0190] When the fluid inlet valve is closed, the pump is controlled to maintain negative pressure in the wound. When the fluid inlet valve is closed, the pump may be controlled to maintain the vacuum pressure in the wound treatment device at a steady state or a constant vacuum pressure level (fourth vacuum pressure). Again, the system may achieve a constant vacuum pressure level after a very short duration, e.g., a few seconds or less, e.g., five seconds or less. When the fluid inlet valve is closed, the controller may operate the pump to achieve the same pressure in the treatment device that the treatment system achieves when the air inlet valve is closed.

[0191] The steady-state vacuum pressure in a wound treatment device with the fluid inlet valve open may be lower than the steady-state vacuum pressure in a wound treatment device with the fluid inlet valve closed. However, the vacuum pressure in a wound treatment device with the fluid inlet valve open is sufficient for effective negative pressure treatment. Treatment fluid is not introduced under positive pressure. Therefore, opening and closing the fluid inlet valve while continuously achieving treatment negative pressure by operating the pump not only maintains a negative pressure environment in the wound for effective treatment, but also provides introduction of treatment fluid and removal of exudate to improve treatment, and reduces the risk of system occlusion.

[0192] The amount of treatment fluid administered to the system can be controlled based on the time the fluid inlet valve is open. A flow restriction (such as a limiting orifice) may be placed between the treatment fluid reservoir 26 and a Pv pressure sensor located upstream of the wound treatment device. The resulting pressure drop across this restriction can allow the fluid velocity to be determined from the resulting pressure drop measured by the sensor Pv, and the total amount of treatment fluid administered to be calculated. Alternatively, the treatment fluid inlet valve may be open until a differential pressure threshold is achieved, or until it is achieved over a certain period of time, or the valve may be open for a predetermined period of time. The treatment fluid inlet valve is preferably opened when the air inlet valve is closed.

[0193] Referring to embodiments in Figures 11 and 12, the system does not have a treatment fluid inlet valve controlled by a controller. The system administers treatment fluid during treatment negative pressure because the vacuum pressure in the wound draws the surrounding treatment fluid into the system. When the air valve is open, air flows into the treatment device, and the flow of air into the system tends to stop the flow of fluid from the treatment fluid reservoir due to the much lower density of air compared to the density of the treatment fluid. When the air inlet valve is closed, the negative pressure in the wound draws fluid from the treatment fluid reservoir into the system, causing it to overflow into the wound. As the pump maintains the vacuum pressure in the wound, the treatment fluid passes through the treatment device and the wound, and through the pump to the reservoir. When the air valve is reopened, the flow of treatment fluid stops again, and the pressure difference moves the fluid, including the treatment fluid and exudate, out of the wound. Thus, circulating the air inlet valve can also achieve the addition of treatment fluid to the wound and the removal of treatment fluid from the wound in a periodic manner. The amount of treatment fluid added depends on how long or how much air is introduced. The amount of treatment fluid introduced into the system may be proportional to the amount of air introduced into the system.

[0194] Here, with reference to Figures 51 to 54, exemplary implementations of the systems in Figures 9 and 10 are described. As illustrated in Figure 51, the controller is configured to implement fluid supply modes or states in addition to the airflow states described above. The controller implements a non-supply / non-airflow mode, in which the air inlet valve and treatment fluid valve are closed and the pump operates to achieve negative pressure at the wound. In the illustrated embodiment, non-airflow states include pressurized, held, and time-out states.

[0195] The airflow and pressurized states in Figure 51 are as described above with reference to Figures 47 and 48. When the airflow and pressurized states in Figures 47 and 48 are activated, the controller implements the fluid supply and holding state in Figure 52.

[0196] Referring to Figure 52, in the holding state, the controller maintains the air inlet valve in the closed position and keeps the pump running, maintaining the desired or acceptable vacuum pressure in the wound treatment device by turning the pump on and off under PID control, for example, to achieve a desired pressure threshold (at Pv or Pp). The controller maintains the vacuum pressure by closing the air inlet valve for a period of time, for example, 20 seconds. After 20 seconds, the controller turns off the pump and checks to see if a fluid supply state is required. If a fluid supply state is not required, the controller returns to airflow mode and the cycle of opening and closing the air inlet valve is repeated as described above with reference to Figure 46. The controller implements a fluid supply state if treatment fluid supply has not been provided for a predetermined period, for example, 8 hours, or if a user-set fluid supply cycle time is triggered, or if the user manually requests fluid supply, for example by pressing a button on the user interface of the vacuum unit.

[0197] The duration during which the fluid supply state is active is much longer than the air inlet valve opening / closing cycle period. For example, the air inlet valve cycle period may be less than one minute, while the duration during which the fluid supply state is active may be more than one hour.

[0198] Referring to Figure 53, in the fluid supply state, the controller opens the fluid valve to allow the treatment fluid to flow from the treatment fluid reservoir to the upstream side of the treatment device, and operates the pump to achieve the pressure threshold. The controller operates the pump when the pressure sensed by the upstream pressure sensor Pv of the treatment device is less than 100 mmHg and the pressure sensed by the downstream pressure sensor Pp of the treatment device is less than 150 mmHg. The control of the pump when the treatment fluid valve is open may be the same as or similar to the control of the pump when the air inlet valve is open, as described above. In the illustrated example, the controller keeps the fluid valve open for 10 seconds, but other periods are possible. The controller may close the fluid valve and allow a fluid contact residence time, allowing the fluid introduced into the wound to overflow or remain at the wound site for a set period. The controller may allow user input to set a residence time of 0 to 10 minutes or other periods. Following a delay to allow fluid contact within the wound, the controller transitions to a flushing cycle to flush the treatment fluid out of the wound. In the illustrated embodiment, the controller repeats the flushing cycle three times, but the controller may perform the flushing cycle one, two, or more than three times. In the illustrated embodiment, the controller repeats the fluid supply state three times before returning to the pressurized state, but the controller may perform the fluid supply state one, two, or more than three times.

[0199] Referring to Figure 54, in the flush cycle, the controller repeats the fluid supply state, continuing the fluid supply state as needed, as shown in Figure 53, and steps through the pressurized state, held state, and airflow state as described above with reference to Figures 48 and 49, before opening the fluid valve again. At the end of the fluid supply state, the controller returns to the pressurized state in Figure 48. The system continues to pressurize, hold the pressure, and cycle through opening and closing the air inlet valve as described above.

[0200] In the illustrated embodiment, the fluid inlet valve is open for 10 seconds and closed for 102 seconds in each opening and closing cycle of the fluid inlet valve. The closing time depends on the residence time and the combined flush cycle execution time. In the illustrated embodiment, the fluid supply state includes three flush cycles. Assuming each flush cycle requires 34 seconds, with respect to an exemplary residence time of zero, in the illustrated example, the fluid supply valve is closed for a total of 102 seconds. In the illustrated example, the fluid inlet valve is open for approximately 10% of the cycle pitch. The fluid inlet valve may be open for at least 5% of the cycle pitch, or at least 10% of the cycle pitch, or at least 20% of the cycle pitch.

[0201] The fluid supply and flushing procedure provides treatment fluid to the wound while maintaining negative pressure, and uses air introduction to flush the treatment fluid from the wound, removing fluid and exudate from the wound. As described above, several treatment fluid flushing procedures may be provided. This procedure reduces stagnant fluid within the wound, thereby reducing blockage in the system and ensuring that negative pressure is continuously applied to the wound site.

[0202] Hereinafter, with reference to Figures 58 to 63, exemplary implementations of the system 400 in Figures 56 and 57 will be described. The system 400 comprises a first connection via an interface sterile manifold connector 20 and connected conduit 5 to an implanted wound treatment device 3 positioned within the internal wound treatment site 4, and a second connection to a trauma treatment device 30 positioned above a closed surgical incision 4a. A preferred trauma treatment device 30 may include a trauma treatment device well known in the art, configured to apply local negative pressure over the entire wound 4a. This locally applied negative pressure may act to "offload" fixation along the primary incision, provided by various mechanical means such as sutures, staples, and / or strips. The trauma treatment device 30 is fluidly coupled to a vacuum unit 2 via a dressing port 31 through a conduit 32.

[0203] The operation of the system 400 is via a user interface 14 that allows the user to selectively operate the system. The user interface may provide the user with visual (e.g., LEDs) and / or audio instructions to communicate system settings. As illustrated in Figure 56, in the system 400, the user interface 14 includes several buttons 23 for starting or stopping the delivery of negative pressure to the connected trauma treatment device 30, turning the unit power on or off, silencing an audible alarm, and / or connecting the device to a remote wireless receiving device to transmit data about the operation or status of the system.

[0204] The controller 17 provides system logic and control algorithms that communicate electrically with actuators for the air valve 18, actuators for the dressing control valve 29, the motor for the pump 15, and pressure sensors Pv, Pp, and Pd. The controller 17 is configured to control the air inlet valve 18, the dressing control valve 29, and the pump assembly 15 based on readings from the pressure sensors Pv, Pp, and Pd. The controller may also communicate with power management and sensor circuits to manage the power supply 16 or provide a battery level warning alarm.

[0205] The controller 17 is configured to operate the pump assembly 15 to maintain negative pressure in the wound 4 via the implanted wound treatment device 3 while opening and closing the air inlet valve 18. While opening the air inlet valve 18 introduces air to the wound site, the pump assembly continues to operate to maintain negative pressure in the wound, as described elsewhere in this specification. Additionally, the controller 17 is configured to open the dressing control valve 29 to send the negative pressure generated by the pump assembly 15 to a fluid-connected wound treatment device 30 positioned above the wound 4a.

[0206] As described herein in relation to other system embodiments, negative pressure treatment may result in a stagnant system that can exacerbate system occlusion due to coagulation of blood, fibrin, etc., in the wound and / or other parts of the system. Occlusion can ultimately lead to a failure to provide negative pressure to the wound, reducing the effectiveness of negative pressure treatment.

[0207] As illustrated in Figure 58, the controller 17 of the system 400 comprises a first control system for the main implanted wound treatment device 3 and a sub-control system for the secondary wound treatment device 30.

[0208] In an exemplary embodiment of system 400, the controller 17 is configured to operate the pump assembly 15 when the system is first turned on to achieve a vacuum pressure level of 100 mmHg at the valve pressure sensor Pv under pressurized conditions. This vacuum pressure level is also referred to as the "Target 1" pressure level at the Pv pressure sensor (see Figure 59). Once system 400 reaches the target vacuum pressure, the system transitions to a hold state illustrated in Figure 60. In the hold state, negative pressure may continue to be applied to the trauma treatment device 30 depending on the operating mode specified by the user.

[0209] Referring to Figure 63, the dressing pressurization state is configured to operate the dressing valve 29 to ensure that a vacuum pressure of 70 mmHg to 95 mmHg, measured by the dressing pressure sensor (Pd) between the dressing control valve 29 and the dressing connection port 31, is supplied to the trauma site 4a. This state remains operational simultaneously while the main wound treatment device control is in a holding state.

[0210] As illustrated in Figure 60, the holding state is configured to maintain the internal wound treatment device 3 at a primary target pressure, which in this example is a target of 100 mmHg when measured at Pv, and a maximum pressure of 150 mmHg is supplied to the pump pressure sensor Pp. The system 400 is held in the holding state for a predetermined period, a duration of 120 seconds in this example. After the predetermined period, the system proceeds to the airflow state illustrated in Figure 61, provided that the Pv vacuum pressure level does not fall below 60 mmHg.

[0211] The airflow illustrated in Figure 61 is similar to the process illustrated in Figure 47. In this example, the controller is configured to target a vacuum pressure level of 80 mmHg when the air inlet valve is open, with a pump pressure Pp. In other embodiments described above, the air valve is configured to remain open for 14 seconds, after which it closes when the system transitions to a pressurized state. Also, as described in relation to other embodiments, the air inlet valve may remain open for 10 to 40 seconds in each air inlet valve open / close cycle, or the duration of the open time may vary otherwise, or it may be configured to detect the equivalent length of the conduit connected to the device.

[0212] In this embodiment, the controller is configured to adapt to expected changes that may occur in the system in response to changes occurring in the wound treatment site 4 and the implanted treatment device 3. When the main treatment device is subjected to repeated cycles across pressurized, held, and airflow states, it has been found that the pressure difference between the Pv pressure sensor and the Pp pressure sensor may occur in response to changes in the treatment site 4 and / or the implanted wound treatment device 3 as a result of internal tissue growth, accumulation of wound debris, and many other factors.

[0213] In response to these dynamic changes, the system adjusts the target pressure level applied to the Pv pressure sensor between pressure points to compensate for the changes in the treatment device 3. For example, if the motor stops as a result of the Pv pressure sensor exceeding 150 mmHg, the system lowers the target vacuum pressure level by 10 mmHg from target 1 (100 mmHg) pressure applied to the Pv pressure sensor to target 2 pressure of 90 mmHg before proceeding to the holding state. If the pressure drop across the entire implanted treatment device 3 increases again, the system continues to lower the target level by one integer until the Pv pressure level reaches a pressure below 60 mmHg (target 5). Once the pressure level measured by the Pv pressure sensor reaches this level, the system stops the transition from the holding state to the airflow state and returns the system to a continuous vacuum pressure level system.

[0214] If the vacuum pressure level at Pv drops below 60 mmHg (Target 5) during the holding state and then returns to 90 mmHg (Target 2), the system will resume proceeding to the airflow state, and the circulation between holding, airflow, and pressurization will resume.

[0215] The time-out condition shown in Figure 62 is similar to the time-out condition in Figure 50, except that the system pauses for 120 seconds before the state progresses towards either a pressurized or airflow state.

[0216] System-specific behavior of trauma treatment devices Referring again to Figures 9 to 12 and Figure 39, the vacuum unit 2 is connected to the treatment fluid source 26 and the wound exudate reservoir 6 via their respective conduits, and to the treatment device 3 via the double-lubricated conduit 5. In some embodiments, the wound treatment device 3 may be a wound dressing 40 (Figure 39), and the wound treatment systems 200, 300 may not include the treatment fluid supply unit 6 (as also described for Embodiment 100 in Figures 2, 3, 6, and 7).

[0217] Such a system can be configured to periodically open the air inlet valve 18 to introduce filtered air into the wound treatment device and achieve a first vacuum pressure level in the absence of treatment fluid supply. The user interface 14 of the vacuum unit 2 may optionally be configured to provide adjustment means such as buttons and / or other suitable user inputs, and corresponding indicators such as graphical scales and / or LED indicator lights, and the adjustment means may allow the user to adjust the air inlet valve opening time to compensate for the level of exudate produced for any given wound and corresponding dressing size.

[0218] The exudate produced, and thus the opening time of the air inlet valve 18, can vary depending on the size, type, or healing progression of the wound. For example, a small wound requiring a 10 cm × 10 cm dressing to cover the wound area with a small amount of exudate may be expected to produce approximately 30 mL of wound exudate per day. 1

[0219] In one exemplary embodiment of the system, a 100 cm long double lumen catheter 5 with a supply conduit 12 having an inner diameter of 1 / 16 inch (φ1.6 mm ID) and a removal conduit 11 having an inner diameter of 3 / 16 inch (φ4.8 mm) contributes a volume of 20 cm to the total free volume occupied by the system. The total free volume is defined as the volume occupied by the inner conduit and the volume occupied by the wound treatment device 40. When a thin non - adhesive dressing system as disclosed in U.S. Patent Application No. 63 / 280787, which is the applicant's application, is applied to a wound with a total dressing height of 5 mm, the volume occupied by the porting layer 41 of the treatment device 40 is approximately 50 milliliters (50 mL), resulting in a total system volume of 70 mL in this example. 3

[0220] ​​In one embodiment, the vacuum unit 2 is configured to supply 3.3V to the pump assembly 15. This results in a free flow rate of air of 178 mL / min, which, calculated for the above example, is required to displace fluid from the system during a single cycle through the airflow state, which is 70 mL or 70 cm³. 3 A minimum air inlet valve cycle time of 23.6 seconds is required to supply that volume of filtered air.

[0221] In an alternative embodiment of a dressing that utilizes an open-cell mesh polyurethane foam component (such as Granufoam®) in the porting layer to treat the aforementioned 10cm x 10cm wound, the volume occupied by the porting layer of the treatment device is equivalent to that of a wound of the same size (78.7cm). 3 foam + 20cm 3 The volume is approximately 98.7 cm³ for a space composed of conduits. Granufoam® PU foam material has been shown to shrink to 100 mm × 104 mm × 25 mm to 82 mm × 96 mm × 10 mm when the wound treatment space is exposed to a vacuum pressure of -150 mmHg. This requires a valve opening time of approximately 33.3 seconds (longer than about 10 seconds).

[0222] In further examples, larger wounds requiring a 25cm x 25cm dressing to cover the wound and accompanied by a large amount of exudate, 1 It can be expected that approximately 1,750 mL will be produced. When the same vacuum unit 2 of the system and wound treatment apparatus of the above-described embodiment is applied to a wound, the total system volume of 332.5 mL is 332 cm³, which is required to displace the fluid during a single cycle through an airflow state. 3 A minimum air inlet valve cycle time of 112 seconds is required to supply a volume of filtered air (332 mL).

[0223] In this example, it may also be advantageous to provide a user interface 14 that provides the user with the option to increase the frequency of the air flow cycle on a given day in order to manage the high levels of exudate in the wound, where in this example, at least 6 cycles are required within a 24-hour period to address the 1,750 milliliters of exudate produced.

[0224] In some systems where the primary dressing is a trauma dressing, the vacuum unit 2 may be further connected to a treatment fluid source 26, as previously described for embodiments 200 and 300 of FIGS. 8 - 12. In such embodiments, the user interface 14 may provide input means that enable the user to adjust the dispensed volume of fluid so as to compensate for the total system volume of the wound treatment system 40.

[0225] In such an embodiment, the user interface 14 of the vacuum unit 2 can provide means for setting the volume of the dressing in an adjustment separate from the adjustment of the level of exudate produced at the wound. The user interface 14 may include a button, for example, that enables the user to set the free volume of the system by pressing and holding the button to draw fluid through the system at a set vacuum pressure level, such as 30 mmHg. The set vacuum pressure level for introducing and holding fluid within the system can be set to any of 10 mmHg to 200 mmHg, but most preferably is 10 mmHg to 125 mmHg.

[0226] The user interface 14 of the vacuum unit 2 may additionally provide means for adjusting the dwell time for which any injected fluid is retained within the treatment device 40. The retention time may be specified as any period, but most preferably is a duration of 1 minute to 30 minutes. The pump unit 2 may additionally include means for oscillating the vacuum pressure level from a first fluid infusion pressure level to a second pressure level, including the durations spent at the first and second pressure levels.

[0227] Other variables that can provide utility for adjustment via the user interface 14 of the vacuum unit include, for example, the operating mode of the pump that switches between a pulsating pressure mode and a continuous supply vacuum pressure mode, or adjusting the time elapsed at each vacuum pressure level.

[0228] Other variables that can provide utility for adjustment are known to those skilled in the art.

[0229] Exemplary Embodiments The effectiveness of a treatment system for removing fluid from a wound according to the present invention is illustrated by the exemplary system configurations described herein.

[0230] The above-described pump having two chambers (see FIGS. 13-16) was connected to a 1 L container. The pump was driven by a 12 V DC motor at a maximum current of 0.25 amperes to apply a vacuum pressure to the container, measure the vacuum pressure inside the container, and obtain the fluid and pressure-related characteristics of the pump.

[0231] The pump characteristics from this test are summarized in Table 1 below.

[0232]

Table 3

[0233] System Components: · A 0.22 micron filter (Steriltech part number PT021350) with a filtration area of 58 mm 2 · An air inlet valve - a mini solenoid valve (KOGE part number KSV2WM-5A) - rated voltage = 4.5 VDC, maximum current 225 mA · The effective inner diameter of the wound treatment device = φ3.7 mm · The effective tube length of the wound treatment device = 470 mm · The internal volume of the wound treatment device = 5.1 mL · The internal volume of the wound treatment device = 5.1 mL • Wound treatment device tube perforation = Two parallel rows of perforations arranged along the effective tube length, 1.5 mm between adjacent perforations, and 2 mm between two parallel rows, each perforation having a diameter of 0.5 mm ± 0.2 mm • Effective inner diameter of the removal conduit = φ3.4mm • Removal conduit length = 1000mm ·Removal pipe volume = 9.1mL • Air supply pipe inner diameter φ1.45mm • Air supply conduit length = 1000 mm • Internal volume of air supply conduit = 1.7 mL • Total system volume (treatment device volume, removal conduit volume, and supply conduit volume) = 16 mL. • Conduit ID = φ3.2mm between the pump and the exudate collection reservoir • Length of the conduit between the pump and the exudate collection reservoir = 300 mm • Reservoir vents = 8 holes, 0.45 microns in size, each with a passage approximately 8 mm in diameter.

[0234] The above system components were set up according to the system configurations shown in Figures 6 and 7, and the wound treatment device was provided in a flexible bag containing 20 ml of fluid to represent the wound treatment space. The system performed three cycles of opening and closing the air inlet valve. Three cycles were repeated with different air inlet valve opening and closing cycle times.

[0235] With the air inlet valve open and airflow flowing, the treatment device maintained a pressure of 50-90 mmHg with a pump pressure of 80-90 mmHg. With the air inlet valve closed and held, the treatment device and pump maintained a pressure of 100 mmHg.

[0236] The amount of fluid remaining in the container was measured after three cycles of opening and closing the air inlet valve. Then, the system was run for 15 minutes while continuing to circulate the fluid by opening and closing the air inlet valve, and the amount of fluid remaining in the container was measured again. The test results are shown in Table 2 below.

[0237] [Table 4]

[0238] An important benefit of the system exemplified by the tests is the effective removal rate of substantially all fluids from the system by cycling the opening and closing of the air inlet valve and leaving the air inlet valve open for a significant portion of the cycle time. In this test, the effective removal of fluid was maximized when the air inlet valve was open for a significant portion (58%) of the cycle period. Further tests showed that further increases in air inlet valve opening time did not result in further improvement in the effectiveness of the system for removing fluid.

[0239] An important factor in the effectiveness of a system for removing fluid from a wound is the ratio of the volume of air introduced into the system in each air inlet valve cycle to the volume of the system, while it is assumed that the opening and closing of the air inlet valve is cycled continuously to maintain the vacuum pressure at the wound at an effective negative pressure treatment level. The volume of air delivered through the system in each valve cycle should be at least a substantial portion of the volume of the treatment system. The volume of the treatment system is defined as the combined internal volume of the supply conduit, treatment device, and return conduit, e.g., the volume of the system from the inlet throttle (inlet filter) to the pump inlet.

[0240] The same test setup as described above was used to determine the volume of air added to the system during the inlet valve cycle, but with a 12.5 mm 2 inlet filter area and a 4.8 mm diameter, 1.5 m long tube representing the supply conduit, treatment device, and return conduit, presenting a system volume of 27 mL. The performance of the system is exemplified by the chart presented in FIG. 55.

[0241] Referring to Figure 55, with the air inlet valve closed, the volumetric flow rate of air during the hold state is 0 L / min. When the air inlet valve is opened and the system transitions to the airflow state, the pressure at the upstream pressure sensor (Pv) drops to approximately 0 mmHg or the ambient pressure level. The pump is controlled to maintain 80 mmHg at the downstream pressure sensor (Pp) during the airflow state. The airflow state operates for 14 seconds. Following the airflow state, the air inlet valve is closed and the system transitions to the pressurized state, in which the pump is controlled to achieve 100 mmHg at the Pv pressure sensor and the volumetric flow rate of air rapidly decreases to 0 LPM. The cycle continues with a further hold state.

[0242] During the airflow state, the air volumetric flow rate reaches equilibrium at approximately 0.111 LPM, or 111 mL / min, after approximately 3.7 seconds of air inlet valve opening. Throughout the entire 14-second duration of the airflow state, the system achieves an average airflow rate of 106 mL / min, which is equivalent to 25 mL of air being delivered through the system. The system has a volume of 27 mL. Therefore, the volume of air delivered through the system in a single 14-second airflow cycle is approximately 75% of the treatment system's internal volume. Increasing the air inlet valve opening time from 14 seconds to 16 seconds will result in approximately 28 mL of air being delivered through the treatment system, which is equivalent to approximately 100% of the treatment system's internal volume.

[0243] For the exemplary setup described above, which includes a total internal volume of 16 mL, similar airflow rates are expected to be achieved during a 14-second valve open duration for the same system operation, resulting in a total volume of approximately 25 mL of air being delivered through the system. This volume of air is approximately 150% of the treatment system volume. It is suggested that the volume of air delivered to the system should be at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 100% of the total system volume. However, tests show that multiple airflow cycles are required to remove approximately 99% of the fluid contained in the treatment site, as indicated by the results presented in Table 2 above. It should be noted that the inlet valve must be cyclically opened and closed. If the air inlet valve is left continuously open or open for an excessively long period of time, annular flow may result. Furthermore, continuously opening the air inlet valve may result in the pump running continuously, which is undesirable for portable systems. It is suggested that the maximum volume of air delivered through the system in a single valve cycle is less than 200% of the total system volume, less than 300% of the total system volume, or less than 400% of the total system volume.

[0244] Simulated occlusion test A series of experiments were conducted to compare the occlusion characteristics of several medium to large commercially available diaphragm pumps with those of the pump described below, referring to Figures 13-16. The test pump device had an inlet 56 with an outer diameter of φ6.8 mm and an inner diameter of φ3 mm, and a pump outlet 57 with an outer diameter of φ4.6 mm and an inner diameter of φ3 mm. The pump inlet channel 61 was connected to two inlet valves 54, which were fluid-connected to two separate chambers 53 having an outlet passage with an outlet channel 62 and two outlet valves 55 fluid-connected to the pump outlet 57. The two inlet valves 54 and the two outlet valves 55 were duckbill valves molded from liquid silicone rubber (LSR), having an overall height of 5 mm and an inner opening of φ2.8 mm that leads to a tapered valve that closes at the valve apex located at the furthest distance from the valve inlet opening. The overall valve assembly corresponds to the cross-sectional view shown in Figure 14.

[0245] The table below summarizes the performance characteristics of the three commercially available diaphragm pumps that were tested.

[0246] [Table 5]

[0247] The test medium was prepared by mixing 30 grams of chia seeds with 300 grams of water (300 mL), stirring, and letting it stand for at least 12 hours to thicken, thereby soaking and softening the chia seeds.

[0248] Chia seeds are typically small, oval-shaped seeds that, when dry, average dimensions of 2.15 mm × 1.40 mm × 0.83 mm. 2 It absorbs a considerable amount of liquid and produces a polysaccharide-based gel. 3 This gel appears to form a sticky, gelatinous substance that exhibits similarities to fibrin or fibrinogen occlusion as it passes through the system.

[0249] For each test, a suitable tube connected the inlet of each diaphragm pump to a glass beaker filled with chia seed gel, and a suitable outlet tube returned the chia seed gel to the same glass beaker. The chia seed gel was aspirated through the pump for several minutes, with the absence of chia seeds passing through the outlet being considered a blockage. Each of the three commercially available diaphragm pump devices blocked in less than one minute, as shown in the table below.

[0250] [Table 6]

[0251] The test pump described herein continuously dispensed chia seed gel into the test beaker for several minutes during the test and showed a passing result.

[0252] Animal experiments A series of animal studies were conducted to compare the effects of various valve cycle timings on the clinical outcomes of seroma prevention in a unilateral sheep external abdominal oblique dead space seroma model.

[0253] In animal experiments, an implanted wound treatment device 3 similar in shape to the one illustrated in Figure 56 was used. The implanted wound treatment device 3 was 18 mm 2 The device had a perforated central conduit 3a approximately 260 mm long, which included a repeating row of four perforations of size φ0.5 mm ± 0.2 mm, spaced approximately 2 mm apart along the central conduit 3a, which had an approximate internal conduit area (equivalent to an inner tube diameter of φ4.8 mm). The implanted wound treatment device had an outer diameter of approximately 120 mm and an inner diameter of approximately 60 mm.

[0254] A removal conduit 11, approximately 1000 mm long and with an inner diameter of 3 / 16 inch (φ4.8 mm ID), was connected to the downstream end 3c of the central drilling conduit 3a, and a supply conduit 12, approximately 1000 mm long and with an inner diameter of 1 / 16 inch (φ1.6 mm ID), was connected to the upstream end 3b of the central conduit 3a.

[0255] Using the treatment algorithm described above in relation to Figures 46 to 50, each implanted wound treatment device was connected to an externally mounted vacuum device 2, which was constructed to reflect the treatment system 100 of the embodiment shown in Figures 6 and 7.

[0256] An external vacuum pump device 2 connected to this implant 3 was configured to open the air inlet valve for 14 seconds, varying the closure duration to evaluate differences in clinical outcomes associated with varying holding lengths. The tests were performed in the "holding state" with valve closure timings of 20 seconds, 120 seconds, 240 seconds, and 360 seconds.

[0257] The system was maintained at a vacuum pressure level of 80 mmHg during the dripping of filtered air in an airflow state, and the system returned to a second equilibrium pressure of 100 mmHg during the pressurized state. This cycle operated in a continuous pattern with the vacuum pressure level along the fluid removal conduit 11 capped at 150 mmHg as a safety mechanism.

[0258] The experiment was conducted on five sheep, each receiving a single implanted wound treatment device 3. The area covered was approximately 110 cm². 2 The defect was created by excising approximately 60 grams of external oblique muscle from a recessed area above the muscle. The implant device was positioned on the lowest ventral lateral side of the defect and secured to the treatment site using a series of ligated sutures to fix the implant in place. Both the removal conduit 11 and the supply conduit 12 emerged from the wound on the uppermost and anteriormost ventral-cranial lateral sides of the wound, and the conduits were held in place in the skin portal using stay sutures. Once the treatment site was closed, the implant device was connected to an externally mounted vacuum pump device 2 and allowed to function as programmed.

[0259] On the 7th postoperative day, an ultrasound evaluation was performed to assess the size of any seroma formed at the defect site, and the volume of any seroma measured at the defect site was calculated using the formula for determining the volume of an ellipsoid.

[0260] The volume of wound exudate collected in the device reservoir was measured daily to determine the total amount of fluid collected over 7 postoperative days. All animals were euthanized on 14 postoperative days, with the exception of animal ID5, which was euthanized on postoperative day 7, and the treatment site was visually evaluated. The results of the animal experiment are shown in the table below.

[0261] [Table 7]

[0262] In animals IDs 1, 2, and 3, which were euthanized 14 days post-surgery, no signs of seroma or wound fluid were found at the defect site, and the implanted wound treatment device 3 was found to be completely integrated with the surrounding tissue.

[0263] In animal ID5, which was euthanized on the 7th postoperative day, there were moderate signs of seroma at the defect site, and the results were consistent with the ultrasound evaluation at the same time.

[0264] The defect site in animal ID4 was found to have a large seroma at 14 days postoperatively, which was consistent with the ultrasound findings at 7 days postoperatively, and there were virtually no signs of any integration of the separated tissue planes of the defect site.

[0265] The results from this animal experiment support the conclusion that an air inlet valve closure time of 120 seconds or less is more likely to result in complete dead space closure and prevention of seroma formation at the defect site by the animals.

[0266] The systems according to the embodiments described herein provide significant benefits, including, but not limited to, one or more of the following: • Improved fluid removal from the wound site, providing improved healing benefits such as reduced edema due to the removal of excess exudate. • Reduce the risk of blockages forming within the system. • Maintain effective negative pressure in the wound, even while adding air, to ensure effective treatment. • Removal of exudate from the lower part of the wound when there is a difference in height between the wounds. • Low power consumption, suitable for use in portable wound care systems. • Applying treatment fluid to wounds while maintaining effective negative pressure to ensure effective treatment. • Providing negative pressure to a larger portion of the treatment space to improve treatment throughout the treatment space. • The configurability of systems with and without the provision of treatment fluids to wounds. • Ease of providing a sterile interface between the air inlet and the wound site.

[0267] References 1.Malmsjo, M., Huddleston, E., & Martin, R. (2014).Biological effects of a disposable, canisterless negative pressure wound therapy system.Eplasty,14.

[0268] 2. Ixtaina, VY, Nolasco, SM, & Tomas, MC (2008). Physical properties of chia (Salvia hispanica L.) seeds. Industrial crops and products, 28(3), 286-293.

[0269] 3. Coorey, R., Tjoe, A., & Jayasena, V. (2014). Gelling properties of chia seed and flour. Journal of food science, 79(5), E859-E866.

Claims

1. 1. A system for treating a wound, comprising: a fluid input and a fluid output for connection to a wound treatment device located at the wound, the fluid input adapted to be fluidly connected to an upstream side of the wound treatment device and the fluid output adapted to be fluidly connected to a downstream side of the wound treatment device; an air inlet valve upstream of the fluid output; an actuator for actuating the air inlet valve between an open position and a closed position; a pump downstream of the fluid input; a motor for driving the pump to provide negative pressure to the wound care device; a controller in communication with the actuator and the motor to operate the air inlet valve and the pump, the controller comprising: i) opening the air inlet valve and operating the pump to maintain a first vacuum pressure in the wound treatment device and introduce air into the wound treatment device; ii) configured to close the air inlet valve and operate the pump to maintain a second vacuum pressure in the wound treatment device and remove air and fluid from the wound treatment device; the first vacuum pressure is less than or equal to the second vacuum pressure; and the controller is configured to repeat steps i) and ii) to cycle the air inlet valve between the open and closed positions.

2. The system of claim 1 , wherein the controller is configured to operate the pump when the air inlet valve is open to maintain a substantially constant first vacuum pressure.

3. 3. The system of claim 1 or 2, wherein the controller is configured to operate the pump when the air inlet valve is closed to maintain a substantially constant second vacuum pressure.

4. The controller: In step (i), opening the air inlet valve and operating the pump such that the system is in equilibrium with zero or a constant pressure difference across the treatment device; and / or In step (ii), closing the air inlet valve and operating the pump such that the system is in equilibrium with zero or a constant pressure difference across the treatment device; The system according to any one of claims 1 to 3, configured to perform one or more of the following:

5. The controller, based on the pressure differential measured across the treatment device, closing the air inlet valve when the pressure differential decreases below a lower threshold. opening the air inlet valve when the pressure differential increases above an upper limit or maximum threshold. Stopping the pump when the pressure differential increases above an upper limit or maximum threshold; Start the pump when the pressure differential decreases below a lower threshold. The system according to any one of claims 1 to 4, configured to perform one or more of the following:

6. 6. The system of claim 1, wherein the controller is configured to operate the air inlet valve between open and closed to introduce air into the system at a flow rate that creates a bubble or slug flow containing air bubbles or slugs entrained in the fluid flow from the wound treatment device.

7. The controller: In step (i), opening the air inlet valve for a predetermined period of time; In step (ii), closing the air inlet valve for a predetermined period of time; and / or In step (i), opening the air inlet valve for at least 10 seconds; The system of any one of claims 1 to 6, configured to perform one or more of the following:

8. 2. The system of claim 1, wherein in step (i), the air inlet valve is opened for a sufficient period of time such that the volume of air delivered to the system is at least 50%, or at least 100%, of a total volume of the system.

9. The system of any one of claims 1 to 8, wherein the first vacuum pressure is about 30% to 100% of the second vacuum pressure.

10. the first vacuum pressure is between about 50 mmHg and 100 mmHg; and The system of any one of claims 1 to 9, wherein the second vacuum pressure is between about 100 mmHg and 150 mmHg.

11. In step (i), the controller is configured to operate the pump to achieve a first vacuum pressure threshold; In step (ii), the controller is configured to operate the pump to achieve a second vacuum pressure threshold; the first vacuum pressure threshold is less than or equal to the second vacuum pressure threshold; A system according to any one of claims 1 to 10.

12. The system further comprises: a downstream pressure sensor located downstream of the wound treatment device and in communication with the controller; 12. The system of claim 11, wherein the controller is configured in step i) to operate the pump to achieve the vacuum pressure threshold based on the pressure sensed by the downstream pressure sensor.

13. The system further comprises: an upstream pressure sensor located upstream of the wound treatment device and in communication with the controller; 13. The system of claim 10, wherein the controller is configured to operate the pump in step ii) to achieve the vacuum pressure threshold based on the pressure sensed by the upstream pressure sensor.

14. A system according to any preceding claim, wherein the system comprises an inlet restriction for presenting a predetermined pressure drop between ambient pressure and a vacuum pressure at the wound care device.

15. 15. The system of claim 14, wherein the pressure drop is between 20 mmHg and 130 mmHg.

16. 16. The system of claim 14 or 15, wherein when the air inlet valve is open, substantially all of the pressure difference between ambient pressure and the pressure downstream of the wound treatment device is at the inlet restriction.

17. 17. A system according to any one of claims 1 to 16, wherein the system comprises a reservoir for collecting fluid removed from the wound, the reservoir being located downstream of the pump such that fluid removed from the wound passes through the pump to the reservoir.

18. The system further comprises the wound treatment device, the wound treatment device comprising: a porting component received within the wound cavity and substantially filling a treatment space of the wound; A covering layer for covering the wound; a fluid supply conduit in fluid communication with the fluid outlet, the fluid supply conduit having one or more supply conduit outlets; a fluid removal conduit in fluid communication with the fluid inlet, the fluid removal conduit having one or more removal conduit inlets; 18. The system of any one of claims 1 to 17, wherein the removal conduit inlet and the supply conduit outlet are in fluid communication with the porting component, and the outlets are spaced from the inlets such that fluid flow from the outlets to the inlets passes through the porting component and a substantial portion of the treatment space.

19. The system according to any one of the preceding claims, wherein the system comprises a treatment fluid inlet upstream of the fluid outlet for connecting a supply of treatment fluid.

20. The system further comprises: a treatment fluid valve between the treatment fluid inlet and the fluid outlet; an actuator for actuating the treatment fluid inlet valve between an open position and a closed position, the controller being in communication with the fluid inlet valve actuator, the controller controlling the fluid inlet valve actuator to: iii) opening the fluid inlet valve and operating the pump to maintain vacuum pressure in the wound treatment device and introduce treatment fluid into the wound treatment device; 20. The system of claim 18, further configured to: iv) close the fluid inlet valve and operate the pump to maintain vacuum pressure in the wound treatment device and remove fluid from the wound treatment device.

21. 21. The system of claim 20, wherein the controller is configured to operate the pump in step (iii) to generate a third vacuum pressure in the wound treatment device, and to operate the pump in step (iv) to generate a fourth vacuum pressure in the wound treatment device, the third vacuum pressure being less than or equal to the fourth vacuum pressure.

22. after closing the fluid inlet valve and operating the pump to generate the vacuum pressure at the wound, the controller: (v) flushing the treatment fluid from the wound, (v)(a) opening the air inlet valve and operating the pump to maintain a vacuum pressure (e.g., the first vacuum pressure) in the wound treatment device and introduce air into the wound treatment device; (v) (b) closing the air inlet valve and operating the pump to maintain a vacuum pressure (e.g., the second vacuum pressure) in the wound treatment device and remove fluid from the wound treatment device, thereby flushing; the controller is configured to repeat steps (v)(a) and (v)(b) a predetermined number of times (e.g., three times) to remove treatment fluid from the wound; and the controller is configured to repeat steps (v)(a) and (v)(b) a predetermined number of times to remove treatment fluid from the wound.

22. A system according to claim 20 or 21.

23. the controller is configured to cycle the fluid delivery state; and A system according to any one of claims 20 to 22, wherein the period between actuating the fluid supply conditions is much longer than the cycle time of the air inlet valve.